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ABSTRACT  
Background. HIV remains one of the leading causes of mortality and morbidity 
worldwide. As the vast majority of HIV infections occurs via unprotected sexual 
intercourses, the development of topical microbicides is a new and promising 
approach to prevent HIV sexual transmission.  
DC-SIGN, a C-type Lectin Receptor (CLR), participates in the initial stages of 
sexually transmitted HIV infection by recognizing highly mannosylated structures 
displayed in multiple copies on HIV gp120. Dendritic cells located in genital 
mucosae internalize HIV through DC-SIGN and transmit the virus in trans to CD4 T 
lymphocytes, promoting virus dissemination. Furthermore, binding of HIV to DC-
SIGN activates signaling pathways that induce immunosuppression and promote 
HIV replication and transmission.  
Thus, inhibition of HIV interaction with DC-SIGN represents a potential therapeutic 
approach to prevent HIV infection at the mucosal level. Aim of this study was to 
evaluate the efficacy in inhibiting HIV infection and the potential toxicity of a 
multimeric glycomimetic DC-SIGN ligand (dendron 12). 
Methods. In the initial phase of this study, the ability of dendron 12 to block 
laboratory and primary HIV-1 strains transmission to CD4 T cells was assessed 
using a trans infection assay in vitro. Owing the results obtained, the efficacy of 
dendron 12 in inhibiting HIV-1 infection of mucosal tissue taken from human uterine 
cervix was evaluated. Cervical explants were treated with the dendron 12 and then 
exposed to different HIV-1 strains in a non polarized manner, mimicking a condition 
of compromised epithelial integrity. Infection was determined by measuring p24 
HIV-1 core protein concentration in supernatants of cell and explant cultures. β 
chemokines production following stimulation of monocyte-derived DCs was also 
analyzed. The selectivity of dendron 12 towards DC-SIGN and Langerin, another 
CLR that recognize high mannosylated structures, was evaluated by Surface 
Plasmon Resonance (SPR) studies. Toxicity of the compound was evaluated in 
both cellular and tissue models.  
Results. Dendron 12 prevented trans infection of CD4 T lymphocytes and infection 
of human cervical tissue by multiple clades of R5 and X4 tropic HIV-1 strains, even 
in presence of elevated viral loads. The compound displayed a prolonged activity 
and absence of toxicity at the highest concentration tested in infection assays. 
Treatment with dendron 12 did not interfere with the activity of Langerin that, in 
contrast to DC-SIGN, prevents HIV transmission promoting the degradation of the 
virus. Moreover dendron 12 significantly elicited the production of the β 
chemokines MIP-1α, MIP-1β and RANTES. The dendron 12 was found to be 
soluble in physiological  media and stable at both neutral and acid pH. 
Conclusion. Dendron 12 inhibits HIV-1 infection by competition with binding of HIV 
to DC-SIGN and stimulation of β chemokines production. Furthermore dendron 12 
is highly soluble in physiological media, stable at acidic vaginal pH, no toxic and 
endowed with a long-lasting effect. Thus, dendron 12 represents a promising lead 
compound for the development of anti-HIV topical microbicides.  
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SOMMARIO 
Introduzione. HIV è tuttora una delle principali cause di mortalità e morbilità nel 
mondo. Poiché la grande maggioranza delle infezioni da parte di HIV avviene 
attraverso rapporti sessuali non protetti, lo sviluppo di microbicidi topici è un nuovo 
e promettente approccio per prevenire la trasmissione sessuale di HIV. DC-SIGN, 
un recettore della famiglia delle lectine di tipo C (CLR), è coinvolto nelle fasi iniziali 
della trasmissione sessuale dell'infezione da HIV, grazie alla sua capacità di legare 
strutture altamente mannosilate presenti in copia multipla sulla glicoproteina 
dell’envelope di HIV gp120. Le cellule dendritiche situate nelle mucose genitali 
internalizzano HIV attraverso DC-SIGN e lo trasmettono in trans ai linfociti T CD4, 
promuovendo la diffusione del virus. Inoltre, il legame di HIV a DC-SIGN attiva vie 
di trasduzione del segnale, che inducono immunosoppressione e favoriscono la 
replicazione e la trasmissione di HIV. L'inibizione dell'interazione di HIV con DC-
SIGN rappresenta quindi un potenziale approccio terapeutico per prevenire 
l’infezione da parte del virus a livello mucosale. Scopo di questo studio è stato 
quindi di valutare l'efficacia nell'inibire l'infezione da parte di HIV e la potenziale 
tossicità di un ligando glicomimetico multimerico di DC-SIGN (dendrone 12). 
Metodi. Inizialmente la capacità del dendrone 12 di impedire la trasmissione di 
ceppi di laboratorio e primari di HIV-1 ai linfociti T CD4 è stata valutata mediante 
un saggio in vitro d’infezione in trans. In seguito è stata valutata l'efficacia del 
dendrone 12 nell’inibire l’infezione di tessuto prelevato dalla cervice uterina umana 
da parte di HIV-1. Gli espianti cervicali sono stati trattati con il dendrone 12 ed 
esposti a diversi ceppi di HIV-1 in modo non polarizzato, simulando la condizione 
in cui l'integrità epiteliale è compromessa. I livelli di infezione sono stati determinati 
misurando la concentrazione della proteina del capside di HIV p24 nei surnatanti 
delle colture cellulari e degli espianti. Inoltre è stata analizzata la produzione di β 
chemochine dopo la stimolazione di cellule dendritiche con il dendrone 12. La 
selettività del dendrone 12 per DC-SIGN e Langerina, un altro CLR che riconosce 
strutture altamente mannosilate, è stata determinata mediante Risonanza 
Plasmonica di Superficie (SPR). Infine è stata valutata la tossicità del composto sia 
nel modello cellulare che nel modello tissutale. 
Risultati. Il dendrone 12 impedisce l’infezione in trans dei linfociti T CD4 e 
l'infezione di tessuto cervicale umano da parte di ceppi di HIV-1 R5 e X4 tropici 
appartenenti a diverse cladi, anche in presenza di elevata carica virale. Il composto 
è caratterizzato da un'attività di lunga durata e assenza di tossicità. Il trattamento 
con dendrone 12 non interferisce con l'attività della Langerina, che a differenza di 
DC-SIGN, impedisce la trasmissione del virus HIV promuovendo la degradazione 
del virus. Inoltre il dendrone 12 stimola significativamente la produzione delle β 
chemochine MIP-1α, MIP-1β e RANTES. Il dendrone 12 mostra elevata solubilità 
nei medium fisiologici e stabilità sia a pH neutro che acido. 
Conclusioni. Il dendrone 12 inibisce l'infezione da HIV-1 sia mediante 
competizione con il legame del virus a DC-SIGN  sia inducendo la  produzione di β 
chemochine. Inoltre dendrone 12 è altamente solubile nei medium fisiologici, 
stabile al pH acido della vagina, privo di tossicità e dotato di un effetto prolungato. 
Alla luce di questi risultati, il dendrone 12 può essere considerato un promettente 
composto lead  per lo sviluppo di microbicidi topici anti-HIV.  
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1. HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
HIV remains one of the leading causes of mortality and morbidity worldwide. The 
virus infects 15,000 people every day and causes millions of deaths every year. 
According to the latest UNAIDS estimates, nearly 33.3 million people are living with 
HIV and about 2.6 million people became newly infected with HIV in 2009.  
The vast majority of HIV-1 infections occurs via sexual transmission through 
mucosal surfaces. Other transmission routes are contaminated needles used for 
intravenous drug delivery, mother to child transmission during perinatal and breast 
feeding period, transfusion of infected blood or therapeutic use of contaminated 
blood products. The latter has been almost completely eliminated, expecially in the 
developed world [1]. 
HIV belong to lentivirus family of animal retroviruses. Lentiviruses, that also 
comprises visna virus of sheep, Bovine Immunodeficiency Virus (BIV), Feline 
Immunodeficiency Virus (FIV) and Simian Immunodeficiency Virus (SIV), cause 
short term cytopathic effects and long term latent infection of the susceptible cells. 
All these virus are responsible of slowly progressive fatal diseases. 
Two types of HIV: HIV-1 and HIV-2, which are closely related to each other, have 
been identified. The more virulent HIV-1 is the most common cause of AIDS 
worldwide, whereas HIV-2 is endemic in West Africa and is now spreading in India. 
HIV-1 and HIV-2 differ in genomic structures and antigenicity, but cause a similar 
clinical syndrome. Both viruses appear to have spread to humans from other 
primate species. The sequence relationships suggest that HIV-1 has passed to 
humans on at least three independent occasions from the chimpanzee (Pan 
troglodytes), and HIV-2 from the sooty mangabey (Cercocebus atys) [2,3].  
1.1 Structure, genome  
Each virus particle, or virion, consist of two copies of an RNA genome and 
associated enzymes (reverse transcriptase, integrase and protese), packaged in 
the viral core and surrounded by the envelope. The core is constituted of the 
capsid p24 protein and surrounded by the matrix protein p17. The envelope is a 
phospholipid bilayer that derived from plasmatic membrane of the infected cell, but 
contains the viral protein gp41 and gp120 (Fig.1). 
The HIV genome is about 9.2 kB long, contains nine genes and, like all 
retroviruses, presents at both the ends LTRs (long terminal repeat sequences).  
LTRs are required for the integration of the provirus into the host cell genome  and 
contain binding sites for gene regulatory proteins that control the expression of the 
viral genes. Like other retroviruses, HIV has three major genes: gag, pol and env. 
The gag gene encodes the structural proteins of the viral core; pol encodes reverse 
transcriptase, integrase and viral protease, involved in viral replication and 
integration; env encodes gp160, precursor of the envelope glycoproteins gp120 
and gp41. HIV genome also contains six smaller genes encoding proteins that 
regulate viral replication and infectivity: tat, rev, vif, nef, vpr and vpu. 
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Figure 1. HIV structure. 
 
1.2 Infectious cycle 
The HIV cycle begins with the entry of the virus in susceptible cells, such as CD4 T 
cells, monocytes, macrophages and dendritic cells (DCs) that express CD4 and a 
co-receptor (CCR5 and/or CXCR4, both members of chemokine receptor family). 
HIV enters into the cells thanks to Env complex, constituted of non-covalently 
associated gp120 and gp41. The complex is a trimeric structure made of three 
gp120/gp41 pairs and mediates fusion of virion envelope with the membrane of 
target cell. Following the binding to CD4, gp120 undergoes a conformational 
change that enables gp120 binding to chemokine co-receptor. This binding causes 
a  conformational change of gp41, that exposed a hydrophobic region, defined the 
fusion peptide. Insertion of the fusion peptide makes possible fusion of the viral 
envelope with host cell membrane and the release of viral core into the cytoplasm. 
Once in the cell, the core releases the RNA genome, which is then transcribed into 
double-stranded cDNA by reverse transcriptase. The viral cDNA enter the nucleus 
in association with viral integrase and vpr protein (that promote nuclear import of 
the viral cDNA) and it is integrated as provirus into host cell genome by the 
integrase. Cell activation enhances integration events. HIV, like other retroviruses, 
Introduction 
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can establish a latent infection in which the provirus remains quiescent for months 
or years. 
The LTRs contain a TATA box promoter sequence and binding sites for the cellular 
transcription factors NFκB and SP1. 
Activation of target cells induces the expression of the transcription factor NFκB, 
which binds to the proviral LTR and initiates the transcription of the HIV genome. 
Activation by cytokines such as IL-2, TNFα and lymphotoxin, antigens and 
polyclonal activators induces HIV gene expression and viral replication in CD4 T 
cells. Exposure to IL-1, IL-3, IL-6 and lymphotoxin induces the same effect in 
monocytes and macrophages. 
Binding of NFκB to the viral LTR, initiates the transcription of viral RNA by the 
cellular RNA polymerase II (RNAPII). However the transcription of HIV genes by  
RNAPII is inefficient. The Tat protein binds nascent viral mRNA and enhances 
RNAPII processivity, allowing the completion of the mRNA transcription. 
Recent studies demonstrated that activation by HIV of both TLR-8 and DC-SIGN 
signaling pathways is required for transcription elongation by RNAPII, resulting in 
full-length HIV-1 transcripts and DCs productive infection (see chapter 3, 
paragraph 8). These transcripts are spliced in various ways to produce mRNAs for 
the viral proteins.  
Regulatory genes are early expressed, whereas structural genes, such as gag, pol 
and env are expressed in a late phase. Tat, Rev and Nef early gene products are 
translated from multiply spliced mRNA, exported from the nucleus by host cell 
nuclear transport mechanisms. The Gag and Pol proteins are translated from 
unspliced mRNA; Vif, Vpr, Vpu and Env are translated from singly spliced viral 
mRNA. Rev promotes export of singly spliced and unspliced transcripts from the 
nucleus. 
The pol mRNAs is translated to give a precursor protein, cleaved by the viral 
protease into reverse transcriptase, protease, ribonuclease, and integrase.  
The gag gene product is a 55kda protein cleaved by viral protease into p24, p17 
and p15. The product of the env gene, gp160, is cleaved by cellular protease into 
gp120 and gp41.  
The full length unspliced RNA transcripts are packaged with the viral protein as 
RNA genome. Then viral particles are enclosed in membrane envelope and are 
released from  the infected cells  by budding [2,3,4].    
1.3 Course of HIV disease 
Few days after virus exposure, abundant HIV replication  occurs in lymph nodes. 
This lead to elevated viremia with spreading of the infection throughout  the body. 
The number of circulating CD4 T cells markedly drops from the normal value (1200 
cells µl-1). Three- six week after infection many infected people develop aspecific 
symptoms, like fever, headhaches, sore throat with pharingitis, lymphoadenopathy  
and rashes (Acute HIV Syndrome). However in several cases primary HIV  
infection is asymptomatic. 
The acute viremia is associated with an early immune response. In virtually all 
patients the activation of CD8 T cells and the anti HIV antibody production  partially 
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control the infection and the viral production. The development of detectable 
antibodies directed against HIV in the blood (seroconversion) occurs six-nine 
weeks after the infection. The cytotoxic T lymphocytes (CTLs), which kill HIV-
infected cells, are important in controlling viremia, that declines to low but still 
detectable levels by about 3 months after the virus exposure.  Similarly, the CD4 T 
cell counts rebound to around 800 cells µl-1. 
Most patients will develop AIDS after a period known as clinical latency or the 
asymptomatic period, during which the immune system can control opportunistic 
infection and no clinical manifestations of HIV infection are present. 
Immune response can control HIV infection, but does not eliminate the virus. 
Indeed HIV evades host immunity in different ways. HIV is characterized by a high 
rate of mutations since viral RT lacks of a proof-reading domain. Mutations that 
occur when HIV replicates can allow variants of the virus to escape recognition by 
antibody or cytotoxic T cells. HIV may evade CTLs also down-regulating MHC I 
expression.  
During the asymptomatic period persistent replication of the virus occurs; CD4 T 
cell destruction in spleen and lymph nodes gradually progresses, leading to a 
gradual decline in the function and numbers of CD4 T cells. Different mechanism 
causes the loss of CD4 T cells in HIV infection: the virus can exert a direct 
cytopathic effect towards infected cells; the infected cells are more susceptible to 
apoptosis or are killed by CTLs. In addition antibody against HIV-1 envelope may 
bind env expressed on surface of infected CD4 T cells triggering antibody 
dependent cell mediate cytotoxicity.  
Once CD4 T cell count is around 500 cells µl-1 the disease  enters the symptomatic 
phase and opportunistic infections and other symptoms appear. This can occur 
between 2 and 15 years, or more, after the primary infection.  
When CD4 T cell counts fall below 200 cells µl-1 cell-mediated immunity is lost, 
viremia dramatically raises and HIV disease progresses to AIDS. Infections with a 
variety of opportunistic microbes (oral Candida species, Mycobacterium 
tuberculosis, herpes zoster) appear. Pneumonia caused by the fungus 
Pneumocystis carinii is common and often fatal. In the final stages of AIDS, 
infection with cytomegalovirus or Mycobacterium avium is more prominent. The 
patients are also affected by tumors like EBV-induced B-cell lymphomas, Kaposi's 
sarcoma and cervical carcinoma. Cachexia (AIDS wasting syndrome), kidney 
degeneration (AIDS nephropathy) and degeneration of central nervous system 
(AIDS encephalopathy) also occur [2,3,4]. 
However the course of the disease can vary widely. A small percentage of people, 
called long-term non progressor (LTNPs) seroconvert, but do not seem to have 
progressive disease. LNTPs maintain a high CD4 and CD8 T cells count, and  
have unusually low plasma HIV RNA levels. Viral, genetic and immunological 
components  seem  to be involved in the control of  HIV infection by LNTPs [5]. 
Some individuals, called HIV exposed seronegative individuals (ESN), do not 
seroconvert  and remain disease-free and virus-negative despite multiple and 
documented exposure to HIV. Some of these people have specific cytotoxic 
lymphocytes and TH1 lymphocytes directed against infected cells. HIV specific IgA, 
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but not IgG were detected in genital tract, saliva and plasma.  Genetic factors, such 
as deletion and polymorphism in CCR5, chemokine variants, HLA polymorphism 
and others, are also involved. However so far, none of the identified immunological 
and ⁄ or genetic mechanism has been able to  completely explain this phenomenon 
[6,7].  
1.4 HIV tropism  
HIV-1 strains that use as co-receptor CCR5, receptor of the β chemokines MIP-1α, 
MIP-1β and RANTES, are referred as R5 tropic. Instead strains that use as co-
receptor CXCR4, receptor of CXC chemokine SDF-1, are defined X4 tropic [8]. 
Env R5 tropic viruses of interacts with the N-terminus of the CCR5 [9], while  Env 
of X4-tropic viruses interacts with the first and second extracellular loops of the 
CXCR4. Initially R5 tropic strains were named “macrophage-tropic” because they 
infect macrophage but not T-cell lines in vitro. Conversely X4 tropic strains were 
defined “lymphocyte-tropic”, as they infect T cell lines and primary CD4 T cells. 
Dual tropic R5/X4 strains can use efficiently both co-receptors  to enter the cells, 
interacting with both N-terminal of CCR5 and first and second extracellular loops of 
CXCR4. However they preferentially exploit  CXCR4 to infect CD4 T cells. 
R5 strains infect CD4 T cells, dendritic cells and macrophages, that express CCR5, 
and require only a low level of CD4 on the target cells. These strains are not able 
to form syncytia and therefore are named non-syncytium (NSI) inducing viruses. 
R5 tropic isolates of HIV predominate during the transmission and are the 
dominant viral phenotype found in newly infected individuals. R5 strains are 
particularly involved in sexual and mother to child transmission. However the 
predominance of R5-tropic viruses occurs regardless of the transmission route as 
they represent the majority of viruses that are found in patients that are infected 
through intravenous drug injection, blood transfusion, or sexual intercourse. 
Infection of CD4 T cells via CCR5 occurs early in the course of infection and 
continues to occur, with activated CD4 T cells accounting for the major production 
of HIV throughout infection.  
Late in infection, the viral phenotype switches to a X4  in about 50% of individuals 
and this is followed by a rapid decline in CD4 T cell count and progression to AIDS. 
To evolve to X4 tropic strains, R5-tropic viruses undergo mutations in the V3-loop 
of gp120. This strains are able to induce syncytia and are referred as syncytium- 
inducing (SI) viruses [8].  
The β chemokines MIP-1α, MIP-1β and RANTES, natural ligands of CCR5, 
suppress HIV-1 R5 tropic strain replication, competing directly with the binding of 
the virus to CCR5 or inducing receptor internalization [10]. 
Some individuals are homozygous for an allelic, nonfunctional variant of CCR5 
caused by a 32-base-pair deletion (CCR5∆32) from the coding region, which 
results in a frameshift and truncation of the translated protein that cannot be 
exported to cell surface. The gene frequency of this mutant allele in Caucasoid 
populations is 0.09,resulting in about 1% of homozygous carriers and about 10% of 
heterozygous [11]. The mutant allele has not been found in Japaneses or Africans 
from Western or Central Africa.  
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People homozygous for CCR5∆32 are highly resistant to R5- and R5X4-tropic HIV-
1 strains. 
Individual heterozygous for CCR5∆32 express low levels of CCR5 and are partially 
protected protection against sexual transmission of HIV, and display low viremia 
reduction in the rate of progression to AIDS. In addition to the structural 
polymorphism of the gene, variation of the promoter region of the CCR5 gene has 
been found in both Caucasian and African Americans. Different promoter variants 
were associated with different rates of progression of disease. 
However rare cases of HIV-1 infection by X4-tropic strains were observed in 
CCR5∆32 homozygotes [12].  
Several studies suggest that other chemokine or chemokine receptor–like orphan 
receptors are used as co-receptor by one o more HIV-1 strains, but the use of 
some of these receptors was demonstrated only in vitro [8]. 
1.5 HIV-1 classification 
Four groups of HIV-1 have been identified so far: M (the “major” group), O (the 
“outlier”), N (“new”) and the recently discovered P. These groups seem to derive 
from at least three distinct passages of simian immunodeficiency virus (SIV) from 
chimpanzee to man. Group M is responsible for  more than 90% of HIV infections  
reported and is sub-classified into nine subtypes or clades. Group O is restricted to 
west and central Africa [13,14]. The group N, phylogenetically equidistant from M 
and O, was firstly described in 1998 in Cameroun and  is very rare [15]. In 2009 a 
new HIV-1 strain was isolated in a Cameroonian woman. This virus, closely related 
to gorilla simian immunodeficiency virus (SIVgor) and distinct from HIV-1 groups M, 
N and O, was designed group P [16].  
Group M is subclassified into nine phylogenetically genetically distinct clades (A, B, 
C, D, F, G, H, J and K). Group M also includes several “circulating recombinant 
forms” or CRFs, that arise when two viruses of different subtypes meet in the cell of 
an infected individual and mix together their genetic material, generating a new 
hybrid virus. Subtype E has never been isolated alone, but CRF A/E exists. 
Similarly subtype I, has been  reclassified as a recombinant form A/G/I. 
The HIV-1 subtypes and CRFs have a distinct geographical distribution. Subtype A 
and CRFs A/G are predominant in West and central Africa. Subtype B is the most 
common subtype in Europe, the Americas, Japan and Australia. It is the 
predominant sub-type found among homosexuals and intravenous drugs abusers 
infected in Europe. However, with increasing immigration and globalization, other 
subtypes are becoming more frequent and now are responsible for at least 25% of 
new HIV infections in Europe. Subtype C is the most abundant subtype in countries 
with the majority of HIV-1 infections. Indeed it Subtype C is present the eastern 
Africa and predominates in all countries of Southern Africa and in some countries 
of Asia, such as India and Nepal. It has caused the world's worst HIV epidemics 
and accounts for around half of all infections. Subtype D is generally limited to East 
and Central Africa. CRF A/E is prevalent in South-East Asia, but originated in 
Central Africa. Subtype F has been found in Central Africa, South America and 
Eastern Europe. Subtype G and CRF A/G have been observed in West and East 
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Africa and Central Europe. Subtype H is present only in Central Africa, J 
exclusively in Central America and K has been isolated in the Democratic Republic 
of Congo and Cameroon. However, due to HIV-1 high rate of mutation, new 
subtypes will probably discovered in the future.   
Clades are classified on the basis of 20-50% differences in the env coding 
sequences. Intra-clade variation of 10-15% is reported. The pol sequences are less 
divergent than env, to avoid that excessive mutations render inactive RT and 
protease. On the contrary gag sequences, encoding for structural proteins of the 
core are quite conserved. Interestingly also LTR display substantial inter-clade 
variations in the LTR copy number and in sequence of enhancer and promoter 
structures, whereas SP1 sites, TATA box and TAT responsive elements are more 
conserved.  
Viruses belonging to different clades display difference in co-receptor usage and in 
capacity to induce syncytia. Clade A and even more Clade C viruses maintain a 
CCR5/NSI phenotype even at later stages of the disease. Clade D maintain a dual 
tropic tropism during all the course of the disease [13,14]. 
AIDS progression may differ in function of infecting subtype. Patients infected by 
Clade C strains appears to undergo more rapid disease progression than patients 
infected by other clades [17].   
1.6 HIV mucosal transmission 
Most of HIV infections are acquired through sexual transmission. The type of 
sexual activity affect the risk of transmission. Initial estimates of transmission rates 
per coital act have ranged from 0·0003 to 0·008, with insertive vaginal intercourse 
associated with lower estimates and receptive anal intercourse associated with 
estimates as high as 0·01 or 1%. Sexual transmission also depends on factors 
such as circumcision status, genital ulcer disease, and phase of disease [18]. 
The vagina and the ectocervix are lined by a thick pluristratified squamous 
epithelium, whereas  epithelium of endocervix and rectum consist of  single layer of 
columnar cells  that may be more easily traversed by HIV and SIV. Rectal mucosae 
contains in subepithelial region many HIV cell target. Furthermore, rectal lymphoid 
follicles contain specialised M cells (microfold cells), which have been shown to 
bind and present HIV-1 to underlying lymphoid tissue.  
Physical abrasion, ulceration, or pre-existing inflammatory conditions, such as 
sexually transmitted diseases and  bacterial vaginosis, cause microulcerations and 
breaks in the epithelium. Hence thinning and breaches in the mucosal barrier could 
expose susceptible cells in the submucosa to virus, increasing the likelihood of 
establishing and rapidly disseminating infection. HIV-1 could traverse the intact 
stratified squamous epithelium of the vaginal mucosa and the simple columnar 
epithelium of the cervix by different ways: transcytosis by epithelial cells, infection 
of intraepithelial lymphocytes, capture or infection of DCs (Fig. 2). 
Epithelial cells selectively capture R5 HIV-1 and then transfer infection to CCR5-
expressing target cells underneath the epithelia, which could account for the 
preferential transmission of HIV-1 strain R5. Interestingly epithelial cells express 
high level of SDF-1 (the CXCR4 natural ligand) providing a barrier for X4 tropic 
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isolates of HIV-1. Langerans cells are located in vaginal epithelium and immature 
dendritic cells (iDCs) are present in subepithelial zone of the different mucosal 
tissues and are among  the first cells encountered by the virus. 
After crossing the epithelial barrier, HIV-1 and SIV can infect CCR5-expressing 
DCs, macrophages and T cells in the underlying mucosal tissues to initiate 
infection. iDCs capture HIV-1 through C-Type lectin receptors (CRLs) (DC-SIGN, 
Mannose receptor) and are productively infected by a CCR5-dependent 
mechanism. Captured virus can be internalized (without productive infection) and 
then rapidly transmitted to nearby CD4 T, most efficiently to CD4 memory subset. 
Virus carrying DCs, after migration to lymphoid organs, also disseminate infection 
to large numbers of CD4 T cells (see Chapter 3 for a more detailed discussion).   
 
 
 
Figure 2. HIV vaginal transmission 
 
Also macrophages, that express mannose receptor and DC-SIGN can transmit the 
virus to CD4 T cells. The acute infection phase is characterized by the infection  
and subsequently the death of memory CCR5+ CD4 T cells in mucosal tissue. As 
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mucosae are the principal localization sites of memory T lymphocytes and contains 
the major reserve of these cells in the body, the loss of CD4 T cells in the mucosae 
leads to a systemic reduction of CD4 T cells. After infection reaches the lymphoid 
tissues, the virus gain access to large numbers of susceptible cells in close 
proximity. In both SIV and HIV infection, although CD4 memory T cells are lost in 
all lymphoid-tissue compartments, the greatest losses happens in the Gut 
Associated Lymphoid Tissue (GALT). 
HIV transmission across the male genital tract is poorly understood. All major 
HIV/SIV target cells (CD4 T cells, Langerhans cells, DCs, and macrophages) 
have been identified in the foreskin and glans pen is. However most CD4 T cells 
reside below the basement membrane in these mucosal tissues, whereas 
Langerhans cells exclusively reside in the epithelium. Ex vivo tissue cultures of 
human foreskin have shown that the it is susceptible to R5 tropic strain infection. 
Like the others mucosal tissues, inflammation of the glans penis  and foreskin 
increases susceptibility to HIV infection [19, 20, 21]. 
1.7 HIV infection therapy  
Treatment of HIV infection is based on drugs that interfere with the viral cycle. The 
first drugs developed were  the nucleoside reverse transcriptase inhibitors (NRTIs), 
that interfere with HIV-1 replication by competitively inhibiting this enzyme. These 
drugs are often effective in reducing HIV levels in the plasma for months or years, 
but  do not stop disease progression as resistances emerge.  
Subsequently protease inhibitors (PI), that bind the active site of HIV protease 
impeding  the cleavage of precursor protein into mature viral capsid and core 
protein, were developed. However when these drugs are used alone resistant HIV 
mutants quickly emerge.  
Protease inhibitors are now being used in combination with two different NRTIs. 
Different studies proved that this triple combination therapy, or highly active 
antiretroviral therapy (HAART), was efficacy in inducing viral load suppression, in 
restoring the immune function and in markedly reducing mortality.  
More recently non-nucleoside reverse transcriptase inhibitors (NNRTIs) were 
developed.  NNRTIs are a group of drugs with different structures that bind the viral 
RT at a region distant from the active site, resulting in conformational changes at 
the active site and consequently in inhibition of RT. NNRTIs are highly specific 
inhibitors with potent antiviral activity in vivo, but they favour  a rapid emergence of 
resistant viral strains if used as monotherapy.  
The introduction of NNRTIs makes feasible the use of other triple combination 
therapies. Indeed NNRTIs combined with two NRTIs are very effective in 
suppressing HIV-1 replication [22]. Recently, integrase inhibitors have been 
successfully introduced into clinical use in combination with others antiretroviral 
drugs [23]. A CCR5 inhibitor, maraviroc was recently approved by the Food and 
Drugs Administration and now is used for the management of R5 tropic HIV-1 
infection in combination with optimized background therapy regimens [24]. 
However HAART is not able to eradicate HIV infection, a life-long treatment is 
required and resistances emerge after long period of treatment. The presence of 
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viral reservoirs represent major obstacle to HIV eradication. Indeed several cell 
types (latently infected CD4 cells, macrophages, that are infected but not killed by 
HIV and Follicular dendritic cells, that trap on their surface large amounts of HIV) or 
anatomical sites (for example central nervous system) are potential HIV reservoirs. 
Moreover even in presence of the HAART low levels of viral replication, below the 
limits of the plasma viral load detection, occur [22]. 
HAART has serious side-effects linked to metabolic complication such as lactic 
acidosis, insulin resistance, abnormalities in lipid metabolism, lipodystrophy. These 
abnormalities in the glucidic and lipidic metabolism may favour the insurgence of 
diabetes and increase the risk of coronary artery calcification and myocardial 
infarction [25,26]. 
Another disadvantage of the HAART, especially for undeveloped countries, is the 
high cost of the therapy. 
1.8 HIV vaccines  
Although many efforts have been devoted to generating HIV vaccines, to date 
there is no approved vaccine on the market. One contribution to vaccine failure 
could be HIV's ability to activate multiple mechanisms of immune downregulation. 
HIV-associated disease is characterized by blunted immune responses, particularly 
those that require T cells. Indeed immune responses against antigens to which the 
host had previously been primed are progressively lost during HIV infection. 
Evolution of mutant virions,  that escape recognition by antibodies and by cytotoxic 
T lymphocytes, makes extremely difficult the development of therapeutic 
vaccination strategies for  HIV-infected patients . 
Strong cytotoxic responses are necessary to provide protection against HIV, but  
such response might be difficult to develop and sustain through vaccination. 
Furthermore the ability of the virus to persist in latent form as a transcriptionally 
silent provirus, might prevent the immune system from clearing the infection once it 
has been established [3,27]. Several vaccine strategies failed to protect against 
HIV-1 infection or to decrease plasma viral load after infection. For example, the 
efficacy Merk’s STEP trial was stopped when early results suggested that not only 
the vaccine was ineffective at lowering post-infection plasma viremia, but people 
receiving the vaccine may have increased their chance of becoming infected with 
HIV-1 [28]. The recent RV144 trial based on a recombinant canarypox vector 
vaccine (ALVAC-HIV) plus two booster injections of a recombinant glycoprotein 
120 subunit vaccine (AIDSVAX) showed only a partial preventative effect. 
Really the vaccine efficacy was 31.2%, but the vaccine did not affect the degree of 
viremia or the CD4 T-cell count in subjects in whom HIV-1 infection was 
subsequently diagnosed [29]. 
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2. TOPICAL MICROBICIDES 
2.1 Importance of developing microbicide drugs 
Thirty years after its discovery,  HIV remains one of the leading causes of mortality 
and morbidity worldwide. Highly active antiretroviral therapy (HAART), has 
markedly reduced morbidity and mortality of HIV infected individuals, but is not able 
to eradicate HIV infection and lifelong treatment is needed. Furthermore such 
treatments are associated with emergence of drug resistance and with serious side 
effects. In addition people living in developing countries often do not have access 
to this expensive therapy (see paragraph 1.7). 
So far, no candidate vaccine was able to prevent HIV infection, with the exception 
of results of RV144 trial, which showed only a very limited preventative effect, and 
no effective vaccine is foreseeable in the immediate future (see paragraph 1.8). 
Proper use of condoms are effective in preventing HIV sexually transmitted 
infection. However, owing to social, ethical, cultural and economic reasons, 
condom use is not yet sufficiently accepted. In this contest there is an urgent need 
for the development of new methodologies of prevention [30]. Women are 
biologically more susceptible to HIV and increasingly bear a disproportionate 
burden of the pandemic. The proportion of women living with HIV worldwide is 
slightly less than 52% of the global total, but the HIV-1 epidemic is increasingly 
affecting woman especially in sub-Saharan Africa, where young women in the age 
group of 15-24 years are eight times more likely to contract the virus compared 
with men [1]. Several factors account for major susceptibility to HIV infection 
difference. Heterosexual intercourse can cause microscopic damage to the lining of 
a woman’s vagina, and these tiny breaches may permit the entry of pathogens. In 
addition, the female reproductive tract provides more surface area for viruses or 
bacteria to invade than the male reproductive tract. Indeed in presence of another 
sexually transmitted disease, the risk of acquiring HIV significantly increases [31]. 
On the other hand receptive anal intercourse associate with an high risk of 
transmission.  
As the vast majority of HIV-1 infections occurs via sexual transmission through 
mucosal surfaces, the development of topical microbicides, formulated for vaginal 
or rectal use, represents a new and promising approach to prevent sexually 
transmitted HIV infection as well as other sexually transmitted diseases (STDs). 
Topical microbicide drugs inhibits early stages of virus infection or replication 
inactivating virus directly, avoiding infection of susceptible cells or blocking virus 
dissemination [30]. 
2.2 Characteristic of an ideal anti-HIV topical microbicide  
In addition to the potent activity against HIV an ideal microbicide should be: 
  
• safe for daily use over long periods of time  
• fast acting and long-lasting in effect 
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• resistant to acidic vaginal pH 
• available in both contraceptive and non-contraceptive formulations 
• suitable for both vaginal and rectal application 
• preferably active also against others sexually transmitted diseases 
• active against HIV and/or other STDs in both ejaculate and cervico-vaginal 
secretions to provide bi-directional protection for both partners 
• stable, even at high temperature 
• acceptable to both sexual partners or completely unobtrusive 
• colorless, odorless and tasteless 
• easy to use, low cost and readily accessible 
 
Furthermore a topical microbicide should not cause epithelial disruption and induce 
inflammation, conditions  that increase the risk of acquiring HIV infection. 
It is also important that topical microbicides do not upset the vaginal or rectal 
microbial ecology, for example by killing Lactobacilli or enhance overgrowth by 
other pathogens. Systemic absorption should be avoided for safety concerns [32]. 
2.3 Preclinical and clinical test to development of topical 
microbicides 
Preclinical or non-clinical testing of microbicides now comprises numerous study 
types. The traditional in-vitro HIV infection models for microbicide testing include 
infection of laboratory cell lines, PBMCs, CD4 T lymphocytes, primary 
macrophages, and dendritic cells by a range of laboratory and clinical virus isolates 
from different HIV clades and with different co-receptor usage. However, ex-vivo 
human explant studies (human penile, cervico-vaginal and rectal explants) are 
important to assess efficacy and toxicity as explant models better approximate the 
in vivo condition (see paragraph 2.4). Also animal models are important to 
determinate efficacy and toxicity. The Rhesus macaque, the pig-tailed macaque, 
and the Cynomolgus monkey model are most relevant for microbicide studies upon 
vaginal or rectal inoculation of SIV or SHIV (a SIV/HIV-1 chimeric clone, used  to 
analyze functions of selected HIV-1 genes in vivo in nonhuman primates).  
Other test required are animal vaginal irritation tests; genetic, general, and 
reproductive toxicity studies; pharmacokinetic studies; safety pharmacology 
studies; carcinogenic studies; hypersensitivity/photosensitivity studies; condom 
integrity studies. Large-scale production capacity, stability, formulation, and costs 
of the candidate microbicide drug are factors to consider before to test the 
candidate microbicide in clinical trials. 
Clinical testing includes: phase I and phase II dosing, safety and acceptability 
studies, penile tolerance studies; phase III trials for efficacy. Phase III trials need 
several thousands of women to be enrolled to give a statistically meaningful result. 
The lower is incidence of HIV infection the higher is the number of people that are 
to be enrolled in the study. The clinical evaluation of microbicides requires that 
sites of the study are able to recruit and retain participants, and can accurately 
estimate HIV and STI incidence, pregnancy rates and normal ranges for clinical 
laboratory measures of health in participating populations. The understanding of 
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women’s and men’s sexual behavior and their risks for HIV and STI infections can 
help researchers interpret clinical trial results [18,33, 34]. 
2.4 Cervical explant model 
Human cervical mucosal tissues has been studied to define HIV target cells in 
genital mucosa, interaction with epithelial cell and susceptibility to R5 and X4 tropic 
strain. Furthermore cervical explants are an useful model to test the efficacy in 
inhibiting HIV infection and the potential toxicity of candidate microbicide drugs 
[35,36].  
Cervical explants are taken from seronegative pre-menopausal women undergoing 
planned hysterectomy and comprises both epithelial and stromal tissue. Non 
polarized and polarized cervical explant model has been described. 
Polarized explants. In this model the tissue is cultured in a polarized state with the 
epithelial surface positioned at the air/tissue interface and the submucosa (stroma) 
submerged in medium. Circular tissue explants are inserted through a hole in a 
transwell insert with the epithelium oriented upward in the apical chamber. The 
epithelial surface of the explant is surrounded with agarose to maintain tissue 
orientation and minimize leakage of microbicides and HIV around the tissue edges. 
The stroma is cultured in medium culture in the basolateral chamber. This 
positioning of the cervical tissue allows application of virus and candidate topical 
microbicides directly to the epithelium, simulating mucosal exposure in vivo, and 
allows access to the cells in the submucosa [37]. However because the tissue 
deteriorates quickly, an accurate monitoring of cell viability and tissue permeability 
is essential [35].  
Non polarized explants. In this system, the tissue is exposed to HIV-1 alone or in 
presence of a candidate microbicide in a non polarized manner. Then the explants 
are maintained in culture submerged in medium. Usually two thirds of the medium 
are changed every two and three days. This model mimics a situation in which 
genital epithelial integrity is compromised [36,38,39,40]. Indeed breaches in 
epithelium are associated with an increased risk to acquire HIV infection.   
Although immune-activation enhance cervico-vaginal tissue infection, R5 tropic 
strains such as the laboratory HIV-1 strain BaL can infect cervico-vaginal tissue  
without immune-activation. On the contrary X4 tropic strain requires 
immunoactivation (e.g with IL-2 and PHA) for productive infection. This is in accord 
with the  epidemiological evidence of a correlation between STDs (that increase 
the recruitment and the activation of HIV cell target) and HIV infection. Pre-
activation of explants with IL-2 and PHA that could mimic aspects of 
infection/inflammation, but the tissues are at least 48 hours old when they were 
exposed to HIV and may be already  deteriorated [35,36].  
Explant were usually exposed to a viral concentration ranging from 103 to 106 
TCID50  (50% tissue culture infective dose) to obtain reproducible levels  of HIV 
infection. Eventual toxicity of compound tested is usually assessed by a MTT 
based assay, that allow to evaluate alteration of the vitality of explants following 
compound exposure [36-40]. 
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Many HIV microbicides test were conducted on stratified squamous vaginal or 
ectocervical tissue because of its relative abundance. However the endocervix, 
lined by monostratified columnar epithelium and rich of HIV cell target in the 
subepithelial zone,  may be more susceptible to HIV infection [35]. 
Cervical explant models have different limitations. Presurgical hormone therapy 
and natural hormonal states of women undergone to hysterectomia may influence 
the results obtained. Numbers, types and activation status of HIV target cells (CD4 
T cells, DC-SIGN+ DCs, Langerhans cells  and macrophages) can vary enormously 
within cervical tissue sites (ectocervix, endocervix, and transformation zone) and 
between individuals.  Important physiological variables such as circulatory support, 
presence of mucus, endogenous normal microflora, are lost.   
Despite these limitation previously described, explants may represent a more 
relevant method of testing topical microbicides than cell-based assays. However 
cell based assays can be more easily standardized.  
Actually explant models present an high intrinsic variability. Furthermore protocols 
of explant infection vary across laboratories. Therefore the results obtained may be 
influenced by several factors including tissue type, HIV-1 strain or isolate, culture 
medium formulation, size of the virus inoculum, culture medium formulation, length 
of virus incubation, frequency of medium change, concentration of test compound, 
drug treatment period prior to or after viral exposure and endpoint viral growth 
measurements.  
However with adequate standardization methods, as suggested by a study of 
Microbicide Quality Assurance Program, explant studies can provide consistent 
evaluation of anti HIV microbicides efficacy [41]. 
2.5 Classification of topical microbicides 
Microbicides can act through different ways and can be classified in different 
groups according to their characteristics and mechanism of action [30,33,18]: 
 
• Surfactants/membrane disruptors 
• Vaginal milieu protectors 
• Viral entry inhibitors 
• Post entry inhibitors (reverse transcriptase inhibitors) 
• Compounds with unknown mechanism of action 
 
Surfactants (nonoxinol-9, C31G, and sodium lauryl sulfate) are the earliest 
compounds developed and evaluated in clinical trials as topical microbicides. 
These compounds disrupt membranes aspecifically, displaying activity against HIV 
and other sexually transmitted pathogens. 
Vagina has an acid pH (3.5 - 4.5)  maintained by commensal lactobacilli, whereas 
semen pH is alkaline (around 7.1 - 8). Vaginal milieu protectors are aimed to 
maintain or restore the acid pH of the vagina. Acidifying gel as Carbopol 974P 
(BufferGel) and Acidform belong to this group. A probiotic strategy, involving the 
use of exogenous lactobacilli for colonization of vaginal canals, was also 
developed.  
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Viral entry inhibitors belong to a wide class of topical microbicides that comprises 
anionic polymers, CCR5 inhibitors, fusion inhibitors and DC-SIGN inhibitors. 
Anionic polymers interact with HIV envelope interfering with the attachment of the 
virus to susceptible cells. However these compounds are more active against X4 
tropic strains, that expose higher level of positive charges on gp120 than R5 tropic 
strains. Nevertheless some of these compounds, such as Naphtalene sulfate (PRO 
2000), Cellulose sulfate (Ushercell) and Cellulose phthalate (CAP), block both R5 
and X4 tropic HIV strains. Since R5 tropic strain predominates in the viral 
transmission, CCR5 inhibitors like PSC-RANTES and CMPD167 were developed 
as topical microbicides. Maraviroc is already used alone or in combination with 
other antiretroviral for treatment of HIV (see chapter 1, paragraph 7). Now 
maraviroc is in preclinical development, alone or associated to others antiretroviral 
drugs [42] and a clinical trial is planned by the International Partnership for 
Microbicides. Fusion inhibitors comprises the clinically approved fusion peptide 
inhibitor enfuvirtide (T-20) and carbohydrate binding agents (CBAs). Among CBAs 
the lectin Cyanovirin-N, that binds high mannose glycans on HIV gp120 is a 
promising compound. DC-SIGN inhibitors will be described in the  chapter 3 
paragraph 9. 
Some Reverse transcriptase inhibitors are currently in clinical trials as topical 
microbicides. The lipophylic NNRTIs TMC-120 (dapivirine) and UC-781 are 
advanced in clinical trials. The CAPRISA study, a two-arm, double-blind, placebo 
controlled trial, recently demonstrated efficacy and safety of a 1% vaginal gel 
formulation of Tenofovir, a NRTI. Tenofovir reduced HIV infection by 50% in 
women with high gel adherence after one year of follow up. However the reduction 
was minor (40%) after 2 years. Low level of tenofovir was detected in the serum, 
but no tenofovir related mutation or mutation conferring multiple resistance to 
NRTIs were reported in seroconverted women. However it is not clear if low level of 
tenofovir absorption are necessary for protection from HIV transmission or if longer 
periods of treatment may induce resistance mutations [43].  
 
More than 70 preclinical and 50 clinical trials have been performed using 
compounds that fall in each of the five classes. However, so far, only tenefovir, 
showed a partial efficacy against HIV-1 infection in a clinical trial.  
2.6 Potential risk associated with microbicide use 
Several microbicide clinical trials were stopped for lack of efficacy or to augmented 
risk of contracting HIV infection. For example both Nonoxinol-9 gel and Cellulose 
Sulfate gel showed increased risk of HIV infection compared to placebo.  
Different biological reasons may explain this phenomenon. Repeated exposure of 
the cervico-vaginal mucosa to a microbicide may lead to changes in epithelial 
integrity and/or permeability, which could facilitate pathogen transmission instead 
of preventing it. As Nonoxinol-9 disrupts the phospholipid membranes, it can cause 
non-specifc damage to genital tissue. Indeed upon treatment with Nonoxinol-9 an 
increase of genital tract lesions with an epithelial breach, which was associated to 
a higher incidence of HIV seroconversion, was observed. Genital epithelial findings 
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and clinical signs of inflammation are therefore essential safety endpoints in clinical 
trials of candidate microbicides. However the individuation of validated biomarkers 
of genital irritation would be useful for standardization of the studies.  
Repeated exposure of the cervico-vaginal mucosa to a candidate microbicide may 
also lead to a subclinical inflammatory reaction, increased immune activation and/ 
or decreased innate immunity. Inflammation can recruit and promote activation of  
HIV target cells. Microbicide may also induce vaginal flora changes. Minor changes 
in the vaginal flora following Nonoxinol-9, Cellulose Sulfate, and Carbopol 974P 
have been reported. However even minor changes of the vaginal flora may be 
associate with bacterial vaginosis and yeast infections, that increases the risk of 
acquiring HIV infection [33,44]. 
2.7 Future perspective 
After mucosal exposure, HIV is able to establishing infection exploiting multiple 
pathways, that involve a variety of target cells (CD4 T lymphocytes, mucosal DCs 
DC-SIGN+, Langerhans cells and macrophages), receptors and co-receptors (CD4, 
CCR5, CXCR4, DC-SIGN and others c-type lectins).  
Defining molecular basis and chronology of early steps of HIV infection and 
identifying the role of different cell types, HIV receptors, co-receptors and host 
factors in facilitating transmission and spreading of the virus may be crucial for the 
rational design of candidate topical microbicides. Indeed, new knowledge about 
early events of HIV infection allows the development of novel molecules that 
interfere with specific molecular and cellular targets during the different steps of 
HIV infection process. The ideal microbicide should be able to interfere with 
different ways of HIV infection mechanisms but should also be able to block HIV 
replication and release once HIV is entered into the cells. The combination of 
microbicides with complementary mechanisms of action is expected to increase the 
potency of the formulation. Indeed, the combinations reported so far were all found 
to display synergistic activity in infection assays. Indeed, at lower concentrations, 
double and triple combinations were generally more effective than individual 
inhibitors. Furthermore the chances of a virus being simultaneously resistant to 
three compounds is less than to any single inhibitor. [30,34].  
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3. DC-SIGN 
DC-SIGN (Dendritic Cell-specific ICAM-3 Grabbing Non-integrin) is a tetrameric 
calcium-dependent transmembrane protein, mainly expressed by dendritic cells 
(DCs) and macrophages.  
DC-SIGN was firstly identified in 2000 as a DC specific c-type lectin that mediates 
adhesion to ICAM-3 on resting CD4 T lymphocytes and regulates DC induced T 
lymphocytes proliferation [45]. 
Additional studies demonstrated that DC-SIGN was identical to the HIV-1 gp120 
binding C-type lectin, previously cloned from a placental c-DNA library, [46] and 
that it mediated capture of HIV-1 and CD4 T lymphocytes infection through a in 
trans mechanism [47]. 
The function of DC-SIGN in HIV-1 infection was further investigated and its 
involvement in the recognition and immune escape of several other pathogens was 
elucidated. 
3.1 Cromosomic localization and structure of DC-SIGN  
The genes encoding human DC-SIGN (CD209), which contains 7 exons and 6 
introns, are located on chromosome 19p13.2-3 and are about 13 kb in length. The 
gene for DC-SIGN is adjacent to gene of CLR CD23 and next to its closely related 
gene, DC-SIGNR or L-SIGN [48,49]. DC-SIGN belongs to C-Type lectins, a 
superfamily of proteins that bind specific sugars in a calcium-dependent manner. 
As most C-type lectins, DC-SIGN is a type II transmenbrane protein. DC-SIGN 
consists of an extracellular domain, a transmembrane region and a cytoplasmic 
domain (Fig. 3).  
 
 
 
 
 
Figure 3. DC-SIGN tetramer structure. 
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The extracellular domain contains a carbohydrate recognition domain (CRD) and a 
neck domain or hinge domain. CRD could recognize specific carbohydrate 
residues like high mannose, Lewisx and mannose-cap (see paragraph 3.8). The 
CRD of DC-SIGN is a globular structure consisting of 2 α-helices, 12 β-strands, 
and 3 disulphide bridges. A loop protrudes from the protein surface and forms part 
of two Ca2+ binding sites (Fig. 4). One of such sites is necessary for the 
conformation of the CRD, and the other is indispensable for direct coordination of 
the carbohydrate structures. Four amino acids (Glu347, Asn349, Glu354 and Asn365) 
interact with Ca2+ at this site and determine the recognition of specific 
carbohydrate structures. Mutations of these sites cause the loss of ligand binding. 
Carbohydrate ligands interact with Ca2+ through hydroxyl groups and with Glu and 
Asn through hydrogen bonds. A valine (Val351) residue in the CRD is involved in 
interaction with some of ligands, suggesting that different ligand have distinct, but 
overlapping, binding sites [50,51].  
 
 
 
Figure 4. Structure of DC-SIGN binding site in the CRD. 
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The neck domain comprises seven or eight complete IgG like tandem repeats and 
one incomplete repetitive sequence, that are required for oligomerization and 
influence carbohydrate specificity. DC-SIGN molecules form tetramers through 
their neck domain, thus allowing high affinity recognition of specific ligands [52]. 
Transmembrane region is essential in localization of DC-SIGN on cell surface. 
The cytoplasmic region contains internalization motifs, such as di-leucine (LL) 
motif, tri-acidic (EEE) clusters and an incomplete immunoreceptor tyrosine based 
activation motif (ITAM). The LL motif and the triacidic clusters are involved  in 
pathogen internalization. ITAM participates in signal transduction [53]. 
In addition to this prototypical structure, alternative splicing events generate DC-
SIGN isoform transcripts whose presence exhibits inter-individual variations. 
Analysis of DC-SIGN neck polymorphisms indicated that the number of allelic 
variants is higher than previously thought and that multimerization of the prototypic 
molecule is modulated in the presence of allelic variants with a different neck 
structure. It was also demonstrated that the presence of allelic variants or a high 
level of expression of neck domain splicing isoforms might influence the presence 
and stability of DC-SIGN multimers on the cell surface [54]. 
Transcripts lacking transmembrane region were also reported. Recently soluble 
DC-SIGN variants (sDC-SIGN) were detected in vitro-generate DC culture 
supernatants as cell free secreted tetramers. Furthermore the presence of sDC-
SIGN was demonstrated in several human body fluids, such as serum, joint fluids 
and bronco alveolar lavages [55]. 
3.2 DC-SIGN expression 
DC-SIGN was firstly identified as specifically expressed by mature and immature 
DCs, but further studies found DC-SIGN expression also by other different cell 
types. 
DC-SIGN is expressed by immature myeloid DCs (iDCs) in mucosal tissue of 
vagina, cervix, rectum, uterus and penis foreskin, in region beneath the epithelium. 
In skin section DC-SIGN was found express on dermal DCs. On the contrary 
Langherans cell residing in epidermis and in stratified epithelia of the vagina, 
ectocervix and foreskin do not express DC-SIGN but a langherans cell specific C-
lectine called Langerin. Furthermore DC-SIGN is expressed by iDCs of placenta 
and lungs. DC-SIGN expressing DCs are present also in T cell areas of lymph 
nodes, tonsil and spleen and in Peyer’s patches. Immature DCs derived from 
monocytes in vitro, a model to study DC function, also express elevated amounts 
of DC-SIGN [45,47,56,57,58,59,60]. 
Monocytes are negative for DC-SIGN, but several studies reported DC-SIGN 
expression by macrophages. DC-SIGN expression was found on macrophages in 
genital mucosae, in lymph nodes and on alveolar macrophages the lung. Subsets 
specialized macrophages in the placenta such as the macrophages of deciduas 
and Hofbauer cells, (fetal macrophages, abundant in chorionic villi) express DC-
SIGN [59,61,62,63]. 
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Although first works [45,47] did not find DC-SIGN expression on B cells, DC-SIGN 
expression by activated B cells was reported by other studies [64,65]. 
It was recently reported that megakaryocytes (MKs, the platelet precursors) and 
the 15% of platelets express DC-SIGN on their surface. The presence of DC-SIGN 
in MKs and platelets was demonstrated by various technical approaches, such as 
RT-PCR, Western blot, flow cytometry, immunoelettromicroscopy [66,67]. 
3.3 Role of DC-SIGN in DC-T cells interaction and in DC 
migration 
DC-SIGN binds the self proteins Intracellular Adhesion Molecule 2 and 3 (ICAM-2 
and ICAM-3), mediating respectively DC migration and DC-T cell interaction.  
Both ICAM-2 and ICAM-3 are glicosylated protein and contain high mannose 
oligosaccharides and Lewisy residues. Removal of these oligosaccharides 
abrogates the binding to DC-SIGN. 
By binding ICAM-2 expressed on endothelium, DC-SIGN acts as a rolling receptor 
and favours migration of precursor DCs from blood. The glycosylation of ICAM-2 
contributes to its recognition by DC-SIGN. Cytokines up regulated DC-SIGN and  
induce migration of precursor DCs from blood into the periphery. Interactions 
between DC-SIGN and ICAM-2 mediate rolling along endothelial vessels and 
transmigration of DCs into the periphery.   
Interaction of Selectin and DC-SIGN with ICAM-2, in presence of chemokines,  
activates integrins such as LFA-1 and induces adhesion. Meanwhile, ICAM-1 up-
regulated by inflammatory mediators strengthens such adhesion through LFA-
1/ICAM-1 interaction. Thus, DC-SIGN/ICAM-2 interaction induces initial adhesion 
of DCs, while LFA-1/ICAM-1 interaction promotes their trans-endothelial migration. 
On antigen challenge, immature DCs will mature and migrate to the lymphoid 
tissues, where ICAM-2 is abundantly expressed on the endothelium of both 
vascular and lymphatic vessels. [68, 69, 70]. 
Interaction between DC-SIGN and ICAM-3 is important in the initial DC-T cell 
contact. Indeed, the initial bind of DCs to ICAM-3, expressed by resting T cells, is 
mediated by DC-SIGN and not by the β2 integrins LFA-1 and αDβ2. The interaction 
between DC-SIGN and ICAM-3, transiently stabilizes the DC-Tcell membrane 
contact to provide efficient TCR engagement. Subsequently the interaction 
mediated by LFA-1 and LFA-3 is required for a more stable DC-T cells contact.  
Hence the transient nature of DC-SIGN/ICAM-3 interaction allows the screening of 
a large number of resting T cells by DCs, until productive  TCR engagement is 
obtained [45,69].  
Some studies showed that binding of DC-SIGN to both CEA-related cell adhesion 
molecule 1 (CEACAM1) and Mac1 is necessary to establish cellular interaction 
between DCs and neutrophils, and such interaction may promote T cell 
proliferation and differentiation to TH1 cells. The ligand recognized by DC-SIGN on  
CEACAM1 is the Lewisx antigens. Thus, the binding of both Mac-1 and CEACAM1 
to DC-SIGN is important for the modulation by neutrophils of T cell responses 
through interactions with DCs [71].  
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3.4 DC-SIGN interaction with pathogens 
DC-SIGN, as well as the others C-type Lectin receptors (CLRs), acts as Pathogen 
Recognition Receptors (PRRs), recognizing specific carbohydrate structures that 
are present on surface of several microorganisms and internalizing microrganisms 
in endosomes and lysosomes through the di-leucine and tri-acidic cluster motifs 
[72].  
DC-SIGN recognizes specific highly-glycosylated structures presented at the 
surface of viruses and non viral pathogens.  
Indeed DC-SIGN recognizes envelope glycoprotein of several virus, such as  HIV-
1, HIV-2, SIV [47,63], Dengue Virus [73], Ebola Virus [74], cytomegalovirus [75] 
(CMV), Hepatitis C virus [76] (HCV), Human T-cell lymphotropic virus type 1 
(HTLV-1) [77], Herpes virus 8 [65,78], Flebovirus [79] and Adenovirus [80,81]. 
Furthermore DC-SIGN binds component of cell wall of some bacteria [72] 
(Mycobacterium tubercolosis, Helicobacter pylori) and yeast (Candida albicans 
[82]) and recognizes also parasites (Leihsmania pifanoi, Schistosoma mansoni) 
[83].  
Several of these pathogens have developed different systems to subvert DC 
functions and to escape immunity through the binding to DC-SIGN.  Binding to DC-
SIGN may promote pathogen infection and dissemination. These pathogens can 
also shift the TH1/TH2 balance towards a TH2 response that favour pathogen 
persistence. These mechanisms have been described in detail for HIV-1. 
3.5 DC-SIGN and HIV infection 
Mieloid immmature DCs located in mucosal tissues of vagina, cervix, rectum and 
penis foreskin, site of entry of the HIV virus,  express DC-SIGN and are proposed 
to be among to first cells to encounter sexually transmitted HIV [19].  
In the vagina and uterine ectocervix DC-SIGN+ DCs are located in subepithelial 
zone. The thick squamous epithelium acts as a barrier to HIV access to DC-SIGN. 
However physical breaches in epithelial integrity, caused by physical abrasion, 
ulceration, or inflammation, provide access for HIV to subepithelial DC-SIGN+ DCs 
and other HIV cell target, strongly enhancing HIV transmission. Rectum and 
endocervix are more susceptible to HIV, being lined by a single layer of columnar 
epithelium. Interestingly recent studies described a more abundant expression of 
DC-SIGN in genital tissue of women and man at risk of infection [84,85].  
DCs through DC-SIGN, by binding HIV-1 envelope glycoprotein gp120, efficiently 
capture the virus, without themselves became infected,  and transmit the virus to 
CD4 T cells (Fig. 5) This particular mode of HIV-1 transmission is called infection in 
trans [47,86]. Moreover DC-SIGN can also facilitate DCs in cis infection.  
In addition, binding of HIV to DC-SIGN induces complex intracellular signal 
pathways that interfere with Toll Like Receptors (TLRs) signalling and help the 
virus to evade immune responses and spread to cells (see chapter 3.6).  
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3.5.1 HIV-1 Infection in trans 
DC-SIGN captures HIV-1 at low titres  by binding with high affinity carbohydrate 
residues on gp120. Captured virion is internalized but escapes, at least in part, 
degradation into lysosomes.  
Indeed a fraction of the virus is degraded in lysosomes and by proteasome and 
presented to MHCII and MHCI [87,88].  
 
  
 
Figure 5. Mechanism of infection in trans.  
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However part of the captured HIV is internalised into the endosomes and 
multivescicolar bodies, intracellular compartments with low pH, where it is 
protected from degradation and retained in a high infective state. Some data 
suggest that DC-SIGN expressed by DCs can retain HIV-1 in a highly infective 
state for more than 5 days, whereas free virus lost is infectivity after a day [47]. 
Neutralisation of the pH of endosomes and multivescicular bodies abrogates DC-
SIGN mediated trans infection [89]. A relation between DC-SIGN ability to bind 
pathogens and  its micro-localisation in plasma membrane was reported. DC-SIGN 
is concentrated in defined microdomains, with an average diameter of 200 nm. 
These microdomains are localized in lipid rafts and are important for binding and 
internalization of pathogens [90]. A clatrin dependent pathway is involved in 
endocytosis  of DC-SIGN and allows recycling back of the receptor to cell surface 
through the di-leucine internalization motif. 
DCs then transmit the virus in trans to nearby CD4 T lymphocytes in genital 
mucosae or, after migration to lymphoid tissue, to CD4 T lymphocytes resident in 
lymphoid tissue, promoting HIV-1 dissemination. 
Viral transmission to target cells occurs across infectious synapses or through HIV 
associate exosomes.  
First studies with MDDCs indicated that cell–cell contact is important for efficient 
CD4 T cell infection. Further studies have disclosed that HIV-1 transmission can 
occur across structures called infectious synapses. The structure of the infectious 
synapse is so called because of similarities to the immunological synapse, which is 
formed between antigen presenting cell and T cell. The set of cell surface 
molecules that contributes to the infectious synapse and are involved in  the 
transfer of HIV-1 from DCs to CD4 T cells has not been fully identified. 
HIV itself and HIV receptors are found concentrated at the infectious synapse, and 
DC-SIGN molecules are also detected at the infectious synapse. These data 
suggest that following contact with CD4 T cells  DCs recycle HIV-1 to membrane, 
facilitating transmission to CD4 T cells. Interestingly, suppression of DC-SIGN 
expression abrogates the formation of the infectious synapse and inhibits trans 
infection of CD4 T cells with X4 HIV strains [91,92,93]. Recent data demonstrated 
that DC-SIGN induced signaling is responsible for viral synapse formation between 
DCs and T cells (see paragraph 3.9). 
However other studies indicated that viral transmission to CD4 T cells can occur in 
the absence of the classically defined synapse. 
Studies reported that endocytic vesicles called exosomes can mediate HIV trans 
infection. HIV-1 captured by immature MDDCs is quickly internalized into 
endosomal multivesicular bodies, endocytic bodies enriched in tetraspanins. 
Interestingly, a part of the endocytosed HIV-1 virions are constitutively released 
into the extracellular milieu associated with exosomes. Then exosomes are 
released in the extracellular space and can fuse with cells target membranes to 
transfer infectious virus [94,95]. The infectious virus that is associated with cell-free 
exosomes is only a part of the total virus that can be measured during synaptic 
transmission. The remaining virus endocytated multivesicular bodies in DCs is 
thought to enter the lysosomal pathway and be degraded [87,88].  
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Therefore, the exosome-release pathway might allow HIV to circumvent 
degradation after capture by DCs. The exosome-associated HIV particles that are 
released from immature MDDCs have been reported to be 10 fold more infectious 
than cell-free viruses on a per-particle basis. In the same way of immature MDDCs, 
HIV trafficking to the infectious synapse between mature MDDCs and CD4 T cells 
also involves a tetraspanin sorting pathway. HIV also exploits the exosome-release 
pathway of mature DCs to facilitate viral transmission and immune evasion [93].  
 
In addition to DC-SIGN the proteoglycan Syndecan 3 and different C-type lectin 
such as Mannose Receptor (MR),  DC-immunoreceptor (DCIR), CLEC 2 and the 
DC-SIGN omologue DC-SIGNR are involved in HIV infection in trans (see 
paragraph 3.6). 
 
Besides DCs other cells types are reported to transmit HIV-1 in trans through DC-
SIGN and other C-Type Lectins.  
Macrophages express DC-SIGN and the mannose receptor and mediate HIV trans 
infection thanks to both these receptors. 
Recent studies showed that DC-SIGN was highly expressed on the surface of 
alternatively activated M2a Monocyte Derived Macrophages (MDMs). Such MDMs 
were able to efficiently transfer HIV-1 to activated PBMCs and T cells through DC-
SIGN. Thus, M2a macrophages expressing DC-SIGN may play an important role in 
the pathogenesis of mucosal infection and in sexual transmission [96,97]. 
 
Intriguily also platelets and megakariocytes were reported to transmit HIV-1 in trans 
(see paragraph 3.5.4). 
3.5.2 HIV-1 infection in cis 
DCs are susceptible to HIV infection but, due to low expression of HIV receptor 
CD4 and of HIV co-receptors CCR5 and CXCR4, efficiency of direct infection of 
DCs is lower than infection of CD4 T lymphocytes. 
DC-SIGN, facilitating HIV interaction with CD4 and co-receptors, enhances DCs 
infection in cis. Indeed it was reported that DC-SIGN, when co-expressed with CD4 
and co-receptors, allowed more efficient infection by both HIV and SIV strains. The 
augmentation of the efficiency of the infection varied from 2- to 40-fold, depending 
on the virus strain. However presence of CD4 and  HIV co-receptor was necessary 
for productive infection [98].  
Different evidences indicate that long-term HIV transmission DCs-mediated 
depends on viral production by the DCs. DCs infection results in de novo 
production and long term transmission of the virus to CD4 T lymphocytes, a 
phenomenon called “second phase transmission” [99]. Several days after viral 
exposure, progeny virions are transmitted to CD4 T cells by infected DCs. After 
exposure to HIV, pDCs and myeloid DCs from human blood can transfer the virus 
to CD4 T cells in the absence of a productive infection. However, after the DCs 
have been productively infected, it is mainly progeny virus that was transmitted to 
CD4 T cells.  
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3.5.3 DC-SIGN and HIV-1 vertical transmission 
Placenta is implicated in a part of cases of HIV-1 vertical transmission from mother 
to child, expecially during the third trimester of pregnancy. Some studies displayed 
that DC-SIGN is expressed on specialized macrophages of placenta: the decidual 
macrophages and the Hofbauer cells (macrophages fetally derived) located in 
chorionic villi. These studies also showed a DC-SIGN implication in HIV-1 vertical 
transmission. 
During pregnancy DC-SIGN expression by Hofbauer cells in the chorionic villi 
increases and this expression has been correlated with increased rates of HIV-1 
vertical transmission. Thus, DC-SIGN can enhance the binding of HIV-1 on the 
surface of Hofbauer cells, providing an efficient mechanism by which the virus can 
be transmitted to target cells in trans. Furthermore Hofbauer cells can be infected 
by HIV-1, expressing CD4, CCR5, CXCR4. Hofbauer cells can entry in contact with 
maternal virus by contact with trophoblasts cells, that are susceptible to HIV-1 
infection. Moreover, breaches in the wall of the trophoblasts can allow a contact 
between fetal Hofbauer cells and HIV-1 particles adsorbed to the maternal decidual 
macrophages or DCs expressing DC-SIGN, present in maternal blood. Hofbauer 
then can transmit the virus to fetus [100,101]. 
3.5.4 DC-SIGN and platelets 
Platelets and megacariocytes (MK) can internalize HIV-1 and a considerable 
amount of HIV-1 in the blood of infected individuals is associated with platelets. 
DC-SIGN is expressed on platelets and MK, efficiently binds HIV-1 and allows virus 
internalization. In MK HIV-1 is internalized in multivescicular bodies. In platelets 
DC-SIGN also accumulates in specific endocytic vescicules and  traffics to surface 
connected canalicular system [66]. Was further demonstrated that captured HIV-1 
was maintained in an infectious state over several days and that  platelets was able 
to transmit in trans the virus susceptible cells. These data suggest that HIV-1 can 
escape degradation by platelets and might use these cells to promote its spread. 
The C-type lectin CLEC2 also expressed by platelets contributes to HIV-1 
internalisation and infection in trans. HIV-1 remains in a infective state for at least 3 
days, a sufficient time frame to allow efficient platelet-mediated HIV-1 
dissemination via the bloodstream [67]. 
3.6 DC-SIGN and other virus infection 
DC-SIGN mediates the infection by several viruses. Mosquito-cell-derived Dengue 
Virus primarily targets immature dendritic cells (DCs) after a bite by an infected 
mosquito vector. DC-SIGN binds envelope glycoprotein E (gE) of Dengue Virus 
and is essential for productive infection of DCs [73] 
DC-SIGN is involved in cellular entry of Ebola virus, by recognizing glycoprotein 
GP. Furthermore, DC-SIGN on the surface of DCs is able to function as a trans 
receptor, binding Ebola virus-pseudotyped lentiviral particles and transmitting 
infection to susceptible cells [74]. 
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DC-SIGN is also required for CMV infection of DCs and is implicated in 
transmission in trans of the virus to fibroblast and endothelial cells. CMV envelope 
glycoprotein B is the ligand of DC-SIGN [75].  
DC-SIGN and its liver homologue L-SIGN/DC-SIGNR (see paragraph 3.8) are 
receptors for HCV envelope glycoproteins E1 and E2. This glycoproteins recognize 
the same binding site on DC-SIGN as HIV-1. Internalized HCV virus-like particles 
are targeted to non-lysosomal compartments within immature DCs, where they are 
protected from lysosomal degradation in similar manner to HIV-1. L-SIGN is largely 
expressed on endothelial cells in liver sinusoids, whereas DC-SIGN is expressed 
on dendritic cells. Capture of circulating HCV particles by these cells DC-SIGN and 
L-SIGN positive facilitates virus infection of proximal hepatocytes and lymphocyte 
subpopulations and may be essential for the establishment of persistent infection 
[76,102,103]. The recent described soluble form of DC-SIGN (sDC-SIGN) is able to 
interact with CMV gB and promotes CMV infection in cis  of DCs [55]. 
It was recently demonstrated that DC-SIGN plays a role in the infection of MDDCs 
as well as model B-cell lines by HTLV-1. Binding of DC-SIGN to HTLV-1 leads to 
productive infection of B-cell lines and MDDCs. Also blood myeloid DCs, in 
presence of  IL-4 production induced by HTLV-1, express DC-SIGN and are 
productively infected by the virus. In addition DC-SIGN mediates HTLV-1 infection 
in trans of T lymphocytes [77]. 
3.7 DC-SIGN homologues 
DC-SIGN homologues from species used as animal models for HIV and AIDS and 
from mice, as this species affords an opportunity to study the normal functions of 
DC-SIGN in vivo, were cloned and characterized. 
Rhesus macaque, pigtailed macaque and chimpanzee DC-SIGN are highly similar 
to the human homologue. The in vivo expression of DC-SIGN in the non human 
primates seems largely similar to the expression in humans. The primate 
homologues are abundantly expressed by DCs in lymphoid tissues such as lymph 
nodes, as well as in mucosal tissues involved in sexual transmission of HIV-1. DC-
SIGN expression on macrophages in both rhesus macaque and chimpanzee 
lymphoid  tissue was also observed. 
These homologues are functionally similar to human DC-SIGN. They bind  HIV and 
SIV strains and  have a high affinity for the immunological ligands of DC-SIGN: 
ICAM-2 and ICAM-3 [104,105]. 
In particular rhesus and pigtailed macaque DC-SIGN have an aminoacidical 
sequence highly similar to human DC-SIGN and differ from each other by only 5 
aminoacids. These homologues share with human DC-SIGN approximately 87% 
amino acid identify overall. The degree of homology was highest in the lectin 
binding domain, with 93% amino acid identity. Endocytosis signals present in the 
cytoplasmic domain and the single N-linked glycosylation site were also conserved. 
The only significant difference was in the repeat region, where rhesus and pigtailed 
macaque DC-SIGN contained 6.5 copies of a 23-amino-acid repeat sequence, 
compared to 7.5 copies in the human protein. However, this do not have significant 
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functional consequences, since both rhesus DC-SIGN and pigtailed macaque DC-
SIGN support HIV-1, HIV-2, and SIV binding and transmission [105]. 
Indeed the homologues bind the HIV-1 envelope glycoprotein gp120 and can act 
as a HIV-1 trans-receptor in the same way as human DC-SIGN, transmitting the 
bound virus to infection susceptible cell types. Antibodies against human DC-SIGN 
cross-react with the primate homologues of  DC-SIGN and inhibit the function of 
these primate homologues. 
Thus primate models and in particular the rhesus macaque model represent a 
potent tool in studying and developing DC-SIGN-based HIV treatment. 
Five mouse genes homologues to DC-SIGN and DC-SIGNR,  called mouse DC-
SIGN, SIGNR1 (SIGN-related gene 1), SIGNR2, SIGNR3, SIGNR4, SIGNR5 were 
cloned. Mouse DC-SIGN is highly expressed in DCs, but not in macrophages and  
it was located in chromosome 8 next to CD23 gene. 
In contrast to primate DC-SIGN, murine DC-SIGN exhibited only a 68% of 
homology to human DC-SIGN in the lectin binding domain and in the 
transmembrane domain of the protein, but the other domains are quite divergent. 
Murine DC-SIGN binds ICAM-3, HIV and SIV strains. However virus bound to 
murine DC-SIGN was not transmitted to receptor-positive cells, indicating that 
binding of virus to a C-type lectin protein does not result in efficient virus 
transmission [105,106].  
DC-SIGN was also reported in other species. For example the cat DC-SIGN 
homologue is critical to cellular entry of Feline Infectious Peritonitis Virus 
[107] and the bovine DC-SIGN gene was recently identified and implicated in 
infection of bovine DCs by Mycobacterium bovis [108]. 
3.8 DC-SIGN signalling 
Binding of pathogens to DC-SIGN induces a transduction signaling pathway that 
interferes with TLRs signaling, modulating immune responses. Upon pathogen 
binding, DC-SIGN induces different pathways converging to activation of 
serin/threonine kinase Raf-1. Specific DC-SIGN ligands induce distinct intracellular 
signalling pathways downstream of Raf-1 that lead to transcription of different gene 
targets and to different immunological responses, depending on the pathogen 
involved. Mycobacteria component ManLAM binds DC-SIGN and interferes with 
TLR4-mediated immune responses by impairing DC-maturation and enhancing IL-
10 production. Similarly, DC-SIGN binding to the Lewis antigens on LPS from 
Helicobacter pylori induces IL-10 production and inhibits TH1 polarization. In 
contrast, LPS from Neisseria meningitidis mutants induces a TH1 response. 
Binding of HIV-1 to DC-SIGN enhances TLR induced IL-10 production [109, 110].   
Upon stimulation, DC-SIGN activates three pathways that converge to activate Raf-
1: a) Ras is activated and binds to Raf-1, inducing conformational changes that 
permit the subsequent phosphorylation of Raf-1 by Src and Pak kinases; b) Src 
kinases induce the phosphorylation of Raf-1 at residue Tyr340/341; c) Rho GTPase-
dependent activation of Pak kinases results in phosphorylation of Raf-1 at Ser338.  
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Raf-1 then phosphorylates NF-κB subunit p65 at Ser276, leading to p65-
acetylation. Acetylation of p65 both prolongs and increases IL-10 transcription, 
resulting in increased IL-10 production. 
Furthermore, DC-SIGN signaling induced by HIV-1 binding triggers effects 
independent of TLR activation. Cross-linking of DC-SIGN with an antibody that 
mimics HIV-1-binding specifically affected the gene expression profile of DCs. 
Genes of MHCII, Jagged 1 and interferon response molecules are down-regulated. 
Other genes such as ICAM-1, the transcription factor ATF3 (a negative regulator of 
TLR4) and the chemokine MIP-1α are up regulated. This indicates that DC-SIGN 
signaling both modulates and represses TLR4 signaling.  
In addition HIV-1 stimulation of DC-SIGN activates the guanine-nucleotide 
exchange factor LARG, that activates the GTPase RhoA, required for the formation 
of viral synapses between DCs and CD4 T cells [111].  
A recent work showed that HIV-1 exploits the innate signaling pathways induced 
via TLR8 and DC-SIGN for its replication and productive infection of DCs. HIV-1 
ssRNA stimulates TLR8 signaling that activates p65 subunit of NF-κB. Activation of 
p65 is necessary for transcription initiation of integrated HIV-1 provirus by RNA 
polymerase II. However a second signal provided by HIV-1 gp120 interaction with 
DC-SIGN is required for transcription elongation by RNAPII. Raf-1 dependent 
phosphorylation of p65 at Ser276, induced by binding of HIV-1 to DC-SIGN, allows 
the recruitment of the transcription elongation factor pTEF-b to nascent transcripts. 
pTEF-b phosphorylates RNAPII at Ser2 promoting transcription elongation by 
RNAPII. Thus, activation of both TLR8 and DC-SIGN signaling pathways results in 
full-length HIV-1 transcripts and DCs productive infection. Subsequently infected 
DCs can transmit the virus to CD4 T cells [112]. 
3.9 DC-SIGN ligands and DC-SIGN inhibitors 
DC-SIGN through its CRD recognizes with high affinity fucose containing 
carbohydrates and mannose containing carbohydrates.  
Indeed DC-SIGN binds with higher affinity Lewis blood-group antigens (Lex, Ley, 
Lea, Leb), that contain fucose residues in different anomeric linkages. On the 
contrary  DC-SIGN is not able to recognise sialyl-Lex, a ligand of L-, E- and P 
selectin. This indicates that DC-SIGN carbohydrate specificity is distinct from that 
of the selectins that mediate leukocyte rolling. Lex antigens are expressed by 
different pathogens. In H. pylori, Lex is present on surface-located LPS, whereas in 
S.mansoni Lex is expressed by all stages of the parasite, including soluble egg 
antigen [113,83]. 
Mannose containing structures are present on the surface of several pathogens, 
such as HIV, SIV, Ebola Virus, Mycobacterium tubercolosis, and Leismania pifanoi.  
DC-SIGN binds both internal mannose branched structures with a minimum of 
three mannose  (high mannose) and end-standing di-mannose.  
The main carbohydrate ligand recognized by DC-SIGN on HIV gp120 as well on 
other pathogens glycoproteins is the high mannose glycan (Man)9(GlcNAc)2, also 
named Man9. High mannose is a branched oligosaccharide, characterized by a 
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structure quite complex, presented in multiple copies on HIV gp120 (Fig. 6). 
[114,53]. 
DC-SIGN is involved in the initial steps of HIV-1 sexually transmitted infection, as 
well as in infection by others pathogens, and therefore may be considered a new 
promising therapeutic target. 
Owing to the role played by DC-SIGN in immunity and infection processes, 
different groups are working to design molecules capable of blocking the 
interaction between DC-SIGN and pathogens, especially HIV-1, in order to prevent 
pathogen transmission and infection. In particular the design and preparation of 
carbohydrate inhibitors of DC-SIGN is receiving increasing interest [115]. 
Because high mannose structure is quite complex, ligands mimicking the whole 
structure are  not suitable for the application in biomedicine. 
However Man9 the terminal disaccharides Mana1-2Man  present on  Man9 arms 
are probably involved in Man9 recognition by DC-SIGN. For example, the 
neutralizing monoclonal antibody 2G12, that recognizes the highly glycosylated 
HIV glycoprotein gp120, interacts with this terminal disaccharide [116]. 
Furthermore fragments of Man9 arms terminated by a di- or a tri-mannoside 
(Manα1-2Man or Manα1-6Manα1-2Man) were reported to bind to DC-SIGN almost 
as efficiently as the entire Man9 [117]. 
 
 
 
Figure 6. Structure of High-mannose-type N-glycans that are abundantly present 
on the envelope glycoprotein gp120 of HIV. Asn, asparagine; Fuc, fucose; Gal, 
Galactose; GlcNAc, N-acetylglucosamine; Man, mannose; SA, sialic acid; Ser, 
serine; Thr, threonine; X, any amino acid except proline. 
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The design and the synthesis of  structural and conformational analogues of Man9 
terminal di- and trisaccharides, were recently reported. Such compounds are more 
resistant to hydrolysis by glycosylases than the corresponding natural 
oligosaccharides and interact efficiently with DC-SIGN. One of these glycomimetic 
compounds exhibited anti-infective action against DC-SIGN-mediated infections by  
Ebola. 
Furthermore these glycomimetics compounds can be easily linked to tetravalent 
(dendron) or polyvalent (dendrimer) scaffolds to augmentate avidity of binding to 
DC-SIGN [118]. 
Indeed another study reported that a mannosylated dendrimer  was able to bind 
DC-SIGN and  to inhibit interaction with HIV-1gp120-coated chips. 
The Wang group reported oligomannose dendrons that display complex 
oligomannoses in high density and inhibit binding of gp120 to recombinant dimeric 
DC-SIGN with IC50 in the nanomolar range [119]. Penadés, Alcami and their 
groups have reported that gold nanoparticles (GNP) displaying various linear and 
branched mannosyl oligosaccharides are potent inhibitors of DC-SIGN mediated 
HIV trans-infection of human activated peripheral blood mono-nuclear cells [120]. 
Although most of the work are focused on mannose or mannose analogues, a 
fucose-based antagonist was recently reported. This new ligand is based on a 
fucosylamide anchor and inhibits DC-SIGN binding to mannosylated BSA (bovine 
serum albumin) with slightly higher potency than the natural ligand Lewisx. Hence 
compounds able to compete with the binding of HIV gp120 to DC-SIGN are 
promising lead compounds in the perspective of developing new topical 
microbicides and HIV entry inhibitors. 
3.10 Other C-type lectin as HIV-1 trans Receptor 
The mannose receptor (MR, designed also as CD206) is a trimeric protein 
expressed by macrophages and by MDDCs. MR recognize mannose containing 
carbohydrates, but with different specificity respect to DC-SIGN. MR can capture 
HIV-1 and transmit the virus to CD4 T cells. Unlike HIV-1 bound to DC-SIGN, HIV-
1 bound to MR has a shorter half-life than free virus. This finding suggest that 
internalization routes of MR and DC-SIGN are different [121,122]. 
The recently described DC immunoreceptor (DCIR) is  transmembrane molecule 
constituted by an intracellular domain containing a ITIM motif, a transmembrane 
domain and an extracellular region that contain a CRD and a neck domain required 
for the oligomerization. DCIR is expressed on APCs (various DC subsets, 
monocytes, macrophages, and B cells). As DC-SIGN, it is down-regulated upon 
maturation of DCs. A recent work showed that DCIR participates in the capture of 
HIV-1 and promotes infection in trans and in cis of autologous CD4T cells from 
human immature MDDCs [123]. 
DC-SIGNR (for DCSIGNRI related) or L-SIGN (Liver and lymph node specific) is a 
homologue of DC-SIGN, firstly described by Soilleux in 2000 [49]. The genes for 
DC-SIGN and DC-SIGNR are highly similar and are localised within a 30-kb region 
on chromosome 19p13.2-3, indicating that duplication of an ancestral gene may 
have happened. DC-SIGNR displays 77% amino acid identity with DC-SIGN. Like 
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DC-SIGN, DC-SIGNR binds to ICAM-3 and is  able to bind and transmit different 
primate lentiviruses (HIV-1, HIV-2, and SIV strains) to susceptible cells. 
DC-SIGNR is expressed by sinusoidal endothelial cells in the liver, endothelial cells 
present in lymph node sinuses, and a significant proportion of capillary endothelial 
cells in term placenta. Expression of DC-SIGNR on DCs or in other tissues has not 
yet been demonstrated [76,102,103].  
Together DC-SIGN, DC-SIGNR is involved in vertical transmission of HIV from 
mother to child [100,101] (see paragraph 3.5.3). Furthermore, like DC-SIGN binds 
HCV glycoprotein E2 and mediated trans infection of liver cell by HCV and is 
involved in Ebola Virus infection. 
3.11 Langerin 
Langerin is a member of C-type lectins superfamily specifically expressed by 
Langherans cells (LCs). Similar to DC-SIGN, Langerin is a type II transmembrane 
protein endowed with an extracellular domain that contains a neck region for 
multimerization and a carboydrate recognizing domain. Like DC-SIGN, Langerin 
recognizes structures with high mannose glycan on HIV-1 gp120, but with different 
specificity. In contrast to DC-SIGN, the murine homologue of Langerin shows large 
similarities to human Langerin, allowing studies on Langerin function in the mouse 
model [124]. 
Recent data demonstrate that Langerin exerts a protective role against HIV 
infection, at least in the presence of low concentration of the virus, promoting rapid 
degradation and clearance of the virus. HIV-1 captured by Langerin was 
internalized into Birbeck granules, subdomains of the endosomal recycling 
compartment. Moreover  Langerin protects LCs, that express CD4 and CCR5, from 
HIV infection and thus prevents LC-mediated HIV-1 transmission. Nevertheless, in 
the presence of high HIV concentration, LCs lose their protective function and can 
mediate infection in trans like DC-SIGN positive DCs or become themselves 
infected [125]. 
LCs are located in the stratified mucosal epithelia of the vagina, ectocervix and 
foreskin, in the epidermis of foreskin, glans penis and skin, but are absent in the 
columnar epithelium of the rectum and the endocervix. LCs protective function may 
explain the low rate of HIV-1 transmission when the mucosal barrier is intact. 
Damage to epithelium allows the contact of  HIV with  DC-SIGN+ DCs increasing 
the risk of HIV infection. Furthermore rectal epithelium contains only DC-SIGN+ 
DCs, and this may be one of the factors that contribute to the higher transmission 
rate of the virus in rectal intercourses.  
 
 
 
 35 
 
 
 
 
MATERIALS AND METHODS 
Material and Methods 
 
 
36 
 
1. VIRUSES                                                              
1.1 HIV-1 strains 
The following laboratory-adapted HIV-1 strains were used in the experiments: the 
R5 tropic HIV-1 BaL (contributed by Drs. S. Gartner, M. Popovic and R. Gallo, 
courtesy of the National Institutes of Health AIDS Research and Reference 
Reagent Program), the R4 tropic HIV-1 IIIB (contributed by Drs. M. Popovic and R. 
Gallo), the dual tropic strain HIV-1 89.6 (contributed by Dr R. Collman) the  R5 
tropic DU174 (Source: Dr. L Morris). All these strains were provided through the 
EU programme EVA centre for AIDS Reagents (The National Institute for Biological 
Standards and Control NIBSC, Potter Bars, UK). Primary isolates HIV-1 V6 (CCR5 
tropic) and V17 (CXCR4 tropic) were kindly provided by Dr. M. Andreoni (University 
of Rome Tor Vergata, Italy). The R5 tropic primary isolate 8g and the R4 tropic 
primary isolate DPMVF  were kindly provided by Prof. Stefano Aquaro (University 
of Rome Tor Vergata, Italy). The HIV-1 strains were grown to high titer in 
Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors. 
1.2 Expansion of HIV-1 strains in PBMCs 
PBMCs from healthy donors (PBMCs isolation procedure from blood will be 
described in the  paragraph 2.3) were seeded at density of 2×106 cells/ml and were 
activated by culturing them in complete RPMI [RPMI 160 with 20% Fetal Bovine 
serum (FBS), penicillin and streptomycin (P/S) and L-Glutamine (LG); all from 
Euroclone (Siziano, Italy)] in presence of IL-2 (15 ng/ml; R&D Systems 
Minneapolis, USA) and PHA (7.5 µg/ml; Sigma Aldrich) for two days. 
60 ×106 activated PBMCs were incubated with different HIV-1 strains 3 hours at 
37°C. After washing PBMC were maintained in culture at density of 106 cells/ml in 
complete RPMI supplemented with IL-2 (15 ng/ml) for 14 days. 
Two times per week the 50% of medium and of the cells was removed and 
replaced with fresh RPMI medium and pre-activated PBMCs. 
Supernatants were collected, aliquoted and stored in liquid nitrogen. Viral 
concentration in supernatants was monitored by p24 ELISA. HIV-1 titer in 
supernatants were subsequently measured by TCID50 quantitation. 
1.3 Determination of  HIV-1 titer by TCID50 quantitation 
Virus load of supernatants of HIV-1 expansion cultures, expressed as tissue culture 
infectious doses (TCID50) were calculated by the accumulative method (Reed-
Muench equation). 
TCID50 is defined as the median tissue culture infective dose; the amount of a 
pathogenic agent that will produce pathological change in 50% of cell cultures 
inoculated.  
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1.3.1 Procedure 
PBMCs from 3 healthy donors were activated with IL-2 and PHA as described 
above.  
At day 0 activated  PBMCs were counted. Six fivefold dilutions of supernatants to 
test were prepared starting with a 1:5 dilution. 105 activated PBMCs (pool of 3 
donors) were seeded in a 96 well plate and were exposed to each viral  dilution (in 
quintuplicate). The negative virus controls consisted in:  
(I) 3 wells containing virus (at the lowest dilution) but without PBMCs  
(II) 3 wells with activated PBMCs but no virus. 
Then the plate was placed in incubator at 37°C and 5% CO2. Two thirds of the 
medium were changed at day 1 and at day 3 post infection. At day 7 post infection 
supernatant were harvested for HIV-1 p24 antigen determination. 
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2. ISOLATION OF CD4 T LYMPHOCYTES AND MONOCYTES 
FROM PERIPHERAL BLOOD  
2.1 Isolation of PBMCs 
Peripheral blood was collected from buffycoat of healthy donors (provided by 
Transfusional Unit of Vimercate Hospital, Vimercate, Italy) following informed 
consent.  
PBMCs were isolated by centrifugation 25 minutes at 2300 RPM, without brake, on 
a Ficoll discontinuous density gradient (Lympholyte-H, Cederlane Laboratories, 
Burlington, NC, USA). 
After the centrifugation step, the blood sample was separated showing the 
following layers from top to bottom (Fig.1): plasma and platelets, the PBMCs band 
situated at plasma/Ficoll interface, Ficoll and red blood cells, covered by a 
granulocyte layer.  
The PBMCs layer were carefully removed from the tube and transferred to a new 
conical tube. The PBMCs were then washed with Phosphate buffered saline (PBS) 
and cell number and cellular vitality were determined. 
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Figure 1. Isolation of PBMCs from pheripheral blood 
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2.2 Cell count 
Cell count was performed with the automated cell counter ADAM-MC (Digital Bio, 
NanoEnTek Inc, Corea). ADAM system provides two kind of staining solution:  
1) AccuStain solution T for total cell counting constituted of Propidium Iodide (PI), a 
fluorescent nucleic acid dye,  and a lysis solution.  
2) AccuStain Solution N for non-viable cells counting, constituted of PI and PBS  
The lysis solution of AccuStain Solution T disrupts cell membranes and allows 
staining with PI to measure total concentration of the cells.  
In AccuStain solution N, live cells remained intact and were not stained. Only death 
cells were stained by PI and were detected. After staining the prepared cells were 
loaded into a chip and inserted into ADAM for cell counting. A 532 nm green laser 
was automatically focused onto the chip and cells that had been stained were 
recorded by a sensitive CCD camera. The image results were automatically 
processed, generating the count of non-viable and viable cells and the percentage 
of viability, which was displayed on the front of the instrument. 
2.3 CD4 T lymphocytes and monocytes magnetic separation 
CD4 T lymphocytes and monocytes were separated from PBMC by direct magnetic 
labelling using the CD4 microbeads or CD14 microbeads respectively (Miltenyi 
Biotech, Bergisch Gladbach, Germany), according to manufacturer’s protocol. 
After determination of PBMCs number, cell suspension were centrifuged at 300×g. 
Pellet was resupended in a specific buffer (containing PBS, 0.5% bovine serum 
albumin and EDTA 2mM) and magnetically labeled with CD4 or CD14 microbeads 
in ice.  
After a 15 minutes incubation at 4°C cell were washed and resuspended in the 
specific buffer. MS columns were placed in the magnetic field of a MACS Separator 
(both from Miltenyi Biotech).  
After rinsing of MS columns  with the buffer, cell suspension were applied onto 
columns for positive selection. Unlabeled cells passed through the column. After 3 
washing steps columns were removed from magnetic separator. 
The magnetically labeled CD4+ lymphocytes or CD14+ monocytes retained in the 
columns  were eluted as positively selected cell fraction. Purity of cell population 
was determined by staining with anti CD4 or anti CD14 antibody and Flow 
Cytometric analysis. 
Cell number and vitality were determined and cells were used for subsequent 
analysis. 
Material and Methods 
 
 
40 
 
3. HIV-1  TRANS INFECTION ASSAY 
3.1 B-THP1/DC-SIGN cells and DC-SIGN ligands 
Human B cell line B-THP1 is derived from Raji B cells and is Epstein Barr virus 
(EBV) positive. B-THP1/DC-SIGN were obtained by transducing B-THP1 with the 
MLV vector MX-DC-SIGN and sorted by Fluorescence Activated Cell Sorting 
(FACS) as a population for high levels of DC-SIGN expression. Parental B-THP1 
are used as negative control in DC-SIGN mediated HIV-1 transmission assay. 
B-THP1 and B-THP1/DC-SIGN (contributed by Drs. Li Wu and Vinet 
N.KevalRamani; courtesy of the National Institutes of Health AIDS Research and 
Reference Reagent Program) were provided through the EU programme EVA 
centre for AIDS Reagents (NIBSC, UK). B-THP1 and B-THP1/DC-SIGN were 
cultured in RPMI supplemented with 10% FBS, P/S and L-glutamine LG.  Both cell 
lines growth in suspension and have a doubling time of approximately one day.  
3.2 Inhibition of Trans infection 
CD4 T cells, (purified as described in paragraph 2.3), were seeded at density of 
2×106 cells/ml and activated by culturing them in RPMI  with 20% FBS, P/S and LG 
in presence of IL-2 (15 ng/ml) and PHA (7.5 µg/ml) for two days. DC-SIGN ligands, 
synthesized by the Department of Organic and Industrial Chemistry of the 
University of Milan, were diluted to desired concentration into culture medium. B-
THP1/DC-SIGN cells or B-THP1 cells (106 cells/ml) were pre-incubated with 
different concentration of compounds 2b, 11, 12, 14  and mannan (Sigma), or with 
culture medium alone (negative control) for 30 minutes prior to exposure to HIV-1 
strains BaL, IIIB, 89.6, V6 or V17 (final concentration of all HIV-1 strain 
corresponding to 10 TCID50) in the continued presence of the inhibitors for 3 hours 
at 37 °C and 5% CO2. After extensive washing, to remove unbound virus and 
inhibitors, B-THP1/DC-SIGN cells were co-cultured with activated CD4 T cells in 
culture medium supplemented with IL-2 (15 ng/ml) at 37 °C and 5% CO2 for three 
days. Cellular concentration of both B-THP1/DC-SIGN cells and CD4 T 
lymphocytes was 2×106 cells/ml and the ratio B-THP1/DC-SIGN: CD4 T 
lymphocytes was 1:4. To evaluate dendron 12 effectiveness in inhibiting infection in 
presence of increasing viral loads B-THP1/DC-SIGN cells or B-THP1 cells (106 
cells/ml) were pre-incubated with dendron 12 (250 µM),  or culture medium alone 
for 30 minutes prior to exposure to HIV-1 BaL (virus titer ranging from 5 TCID50 to 
80 TCID50), in the continued presence of the inhibitor for 3 hours. Subsequently B-
THP1/DC-SIGN cells were co-cultured with activated CD4 T cells, as described 
above. For some experiments B-THP-1/DC-SIGN cells were treated 30 minutes or 
2 hours with the inhibitor or medium alone and washed with PBS to eliminate 
unbound compounds. After wash B-THP-1/DC-SIGN cells were put in culture 
medium and then were exposed 3 hours to HIV-1 BaL (10 TCID50) immediately or 
after 6 or 12 hours. After incubation with the virus the cells were the co-cultured 
with CD4 T lymphocytes, as previously described.  
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4. HUMAN CERVICAL EXPLANTS INFECTION 
Cervical tissue was obtained from premenopausal women (following written 
informed consent), HIV, HBV and HCV seronegative and without current genital 
infection, undergoing planned therapeutic hysterectomy at Sacco hospital (Milan, 
Italy). Endocervical 3 mm x 3 mm explants biopsies, comprising both epithelium 
and stromal tissue, was produced using a 3 mm diameter biopsy punches. 
Tissues were transported in HBSS with phenol red medium (Lonza, Basel, 
Switzerland) containing 10% fetal bovine serum (FBS), penicillin and streptomycin, 
L-glutamine (all from EuroClone, Italy) and 62,5 µg/ml gentamycin (Sigma, Saint 
Louis, Missouri, USA).  
After washing the explants were either immediately treated with dendron 12 and 
infected with R5 tropic strains or were pre-stimulated for 2 days in presence of IL-2 
(15ng/ml) and PHA (7.5 µg/ml) prior to X4 tropic HIV-1 DPMVF exposure in a non 
polarized way. More in detail,  explants were pre-treated 30 minutes at 37 °C  with 
different concentration of tetravalent dendron 12 diluted into culture medium  or 
with culture medium alone (control). Afterwards explants were exposed to HIV-1 
BaL (2.6 ×104 TCID50), 8g (104TCID50), DPMVF (104 TCID50) or DU174 (104 
TCID50) in the continued presence of tetravalent dendron 12 for 3 hours at 37 °C. 
Subsequently explants were washed with RPMI to remove residual virus and 
compounds.  
Unstimulated explants were cultured in RPMI medium supplemented with 20% 
FBS, penicillin and streptomycin(P/S), L-glutamine (LG) (all from Euroclone) and 
gentamycin (Sigma) at 37 °C and 5% CO2. Stimulated explants were cultured 
under  the same conditions in presence of IL-2 (15 ng/ml). Two third of the medium 
culture were repaced with fresh medium at day 3. 
Supernatants of tissue culture were collected at day 3 and 7 post infection and 
assayed for p24 concentration. 
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5. DIFFERENTIATION OF IMMATURE DENDRITIC CELLS FROM 
MONOCYTES 
CD14 positive monocytes were isolated from healthy donors peripheral blood as 
previously described (see paragraph  2.3). 
Purified monocytes (106 cells/ml)  were  differentiated into immature Dendritic Cells 
(iDCs) by culturing them in RPMI with 10% FBS, PS, LG in presence of 
recombinant human IL-4 (20 ng/ml) and GM-CSF (20 ng/ml) (both from R&D 
Systems) for 6 days. 
The 50% of culture medium was replaced at day 3 with fresh medium containing 
IL-4 and GM-CSF. 
At day 6 the Monocyte Derived Dendritic Cells (MDDCs) were analyzed for the 
expression of DC-SIGN and of others surface markers typical of myeloid DCs. The 
absence of monocyte marker CD14 expression was also confirmed.  The analysis 
was performed by flow cytometry (see chapter 7). 
MDDCs were plated at 2×106 cells/ml in RPMI plus P/S, LG and 10% FBS in 
presence or absence (control) of dendron 12 (250µM) for 3, 24 or 48 hours. 
RNA was extracted from MDDCs culture to evaluation of chemokine expression 
(see chapter 8). Supernatants were harvested and MIP-1α, MIP-1β and RANTES 
concentration in was evaluated by ELISA (see chapter 6). 
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6. ELISA 
6.1 p24 ELISA 
Co-culture supernatants were collected at day 3 post infection for trans infection 
assay and at day 3 and day 7 for cervical explant infection assay. p24 
concentration, as a measure of HIV infection, was assayed using the Alliance HIV-
1 p24 Antigen kit (Perkin Elmer, Boston, USA) following manufacturer’s 
instructions. Microplate wells are already pre-coated with a monoclonal antibody 
endowed with a high specificity and affinity to HIV-1 p24. Standards and samples 
(when needed) were diluted in inoculated culture medium. A five point standard 
curve using two-fold serial dilution and an high standard of 100 pg/ml were 
prepared. A linear standard curve was generated. Firstly Triton X-100 was added 
to all microplate wells (except substrate blank) to disaggregate HIV-1 virion, then 
the standards and samples were added to designated wells and the plate were 
incubated 2 hours at 37 °C. Plate were washed with wash buffer (phosphate buffer 
plus 1% Tween-20). Biotinylated polyclonal antibody to HIV-1 p24 was added to all 
wells except substrate blank at 37 °C for 1 hours. After washes Streptavidine 
conjugated with the horseradish peroxidase was added and the microplate was 
incubated 30 minutes at room temperature (RT). After washing the chromogenic 
substrate ortho-phenilenediamine-HCL (OPD) were added 30 minutes to all wells 
at RT. Following incubation with OPD, yellow color directly proportional to amount 
of p24 captured was generated. Reaction was stopped by adding stop solution (4N 
sulfuric acid) to all wells. Plates were immediately read at 490 nm, with the 
correction wavelength set at 655 nm, using the IMark microplate reader equipped 
with Microplate Manager ® 6 software (both from Biorad, Segrate, Italy). 
6.2 β Chemokine ELISA 
MIP-1α, MIP-1β and RANTES concentration in supernatants of iDCs culture at 24 
and 48 hours was evaluated using specific DuoSet kit  (all from R&D Systems). 
Plates were coated with Capture antibody specific to MIP-1α, MIP-1β or RANTES 
overnight  at room temperature. Plate were then washed 3 times with wash buffer 
(0.05% Tween-20 in PBS) and blocked with Reagent diluent (1% Bovine Serum 
Albumine, BSA, in PBS) for 1 hour. Subsequently standard and samples were 
added to designated well. A seven point standard curve using 2-fold serial dilutions 
was used. The  high standard was of 500 pg/ml for MIP-1α and  MIP-1β and of 
1000 pg/ml for RANTES. A 4 Parameter Logistic (4-PL) standard curve was 
generated. After washing biotinylated  detector antibody was added and incubated 
2 hours at RT. Plate was washed as described and Streptavidine was added to all 
wells 20 minutes. After washing substrate solution (1:1 mixture of Color Reagent A, 
H2O2, and Color Reagent B, Tetramethylbenzidine) was added to each well. After a 
20 minutes incubation stop solution (2N was added sulfuric acid). The optical 
density of each well was  read at 450 nm, with the correction wavelength set at 595 
nm. Plates were read using the IMark microplate reader. 
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7. FLOW CYTOMETRY 
DC-SIGN expression in the cell line B-THP1/DC-SIGN was checked by staining 
with the anti-human DC-SIGN PE monoclonal antibody (clone AZND1, Beckman 
Coulter, Miami, USA).  
To confirm differentiation of monocytes to iDCs and DC-SIGN expression  2×105 
cells were stained with the following anti- human monoclonal antibodies:  
CD14 PE-cy7 (mouse IgG2a, clone RMO52), CD11c PE-cy5 (mouse IgG1, clone 
BU15), CD86 PE (mouse IgG2b, clone HA5.2B7) CD83FITC (mouse IgG2b, clone 
HB15a), DRII PE (mouse IgG1, clone Immu357), DC-SIGN PE (all from Beckman 
Coulter). 
Cells were resuspended in PBS and stained with the indicated antibodies. After 15 
minutes of incubation at room temperature in the dark cells were washed with PBS 
and fixed in 1% of formaldehyde (Sigma). 
To evaluate the toxicity of dendron 12 B-THP-1/DC-SIGN cells were incubated with 
different concentrations of the compound for 3 hours and 30 minutes. To evaluate 
the toxicity of 12 PBMC were incubated with different concentrations of 12 (0.25 
mM, 0.5 mM, 1 mM) for 3 or 7 days. After the incubation period with the dendron 
12, the cells were stained with DNA incorporating dye 7-aminoactinomicyn D (7-
AAD, Beckman Coulter) for 15 minutes at room temperature in the dark. After that 
500µl of PBS were added and preparation were analyzed by flow cytometry.  
The apoptosis was monitored evaluating the number of dead cells according to 
forward and side scatters of flow cytometric  analysis and the staining with 7-AAD. 
All flow cytometric analyses were performed using a CYTOMICS FC-500 flow 
cytometer equipped with a double 15-mV argon ion laser operating at 456 and 488, 
interfaced with CXP 21 software (Beckman Coulter). Green fluorescence from 
FITC was collected through a 525 nm band pass filter (FL1), orange-red 
fluorescence from PE  was collected through a 575 nm band pass filter  (FL2), red 
fluorescence from 7-AAD was collected through a 620 nm band pass (FL-3), red 
fluorescence from PE- Cy5 was collected through a 670 nm band pass filter (FL4), 
deep red fluorescence from PE- Cy7 was collected through a 755 nm band pass 
filter (FL-5). Data were collected using linear amplifiers for forward and side scatter 
and logarithmic amplifiers for FL-1, FL-2, FL-3, FL-4 and FL-5. 
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8. RNA EXTRACTION AND REAL TIME PCR 
8.1 RNA extraction 
RNA was extracted from cultured iMDDCs by using the acid guanidium 
thiocyanate–phenol–chloroform method. RNAzol B reagent (TEL-TEST, Inc., 
Duotech, Milan, Italy), a monophase solution containing phenol and guanidine 
thiocyanate, was used.  
MDDCs were lysed in RNAzol B and the lysate were separated into aqueous and 
organic phase by the addition of chloroform (20% of RNAzol B initial volume used). 
Samples were centifuged (at 12,000g 15 minutes at 4°C) to efficiently remove DNA 
and proteins from the aqueous phase containing RNA. The undegraded, pure RNA 
is obtained from the aqueous phase by the isopropanol precipitation and  washing 
with 75% ethanol.  
8.2 DNAse treatment and retrotranscription 
The RNA was dissolved in RNase-free water, and purified from genomic DNA with 
TURBO DNAse (Applied Biosystems/Ambion, Austin, TX), a genetically engineered 
form of bovine DNase I with greater catalytic efficiency than conventional DNase I 
at higher salt concentrations and lower DNA concentrations. A reaction mixture, 
containing 1µg of RNA, Turbo DNasi 1U and TURBO DNasi Buffer, were incubated 
30 minutes at 37 °C. Then  DNase was inactivated by DNase inactivation reagent 
(Applied Biosystems/Ambion), that binds and removes the divalent cations from 
DNase. 
1 µg of RNA was reverse transcribed into first-strand cDNA in a 20-µl final volume. 
A reaction mixture,  containing 1 µM random hexanucleotide primers, 1 µM oligo 
dT and the RNA,  was heated at 70 °C for 5 minutes to melt secondary structure 
within the template. The mixture was immediately cooled on ice to prevent 
secondary structure from reforming. A dNTPs mix,  200 U Moloney murine 
leukemia virus reverse transcriptase (M-MLV RT),  20 U Recombinant RNasi 
inhibitor and M-MLV 5X reaction buffer were added (all from Promega). The 
reaction mix were incubated 60 minutes at 42 °C and then heated 5 minutes at 95 
°C to inactivate the RT.  
8.3 Real time PCR  
cDNA quantification for MIP-1α, MIP-1β, RANTES and GAPDH was performed by 
real-time PCR (DNA Engine Opticon 2; MJ Research, Ramsey, MN). Reactions 
were performed using a SYBR Green PCR mix (Finnzymes, Espoo, Finland). 
SYBR green is a fluorogenic minor groove binding dye that exhibits little 
fluorescence when in solution but emits a strong fluorescent signal upon binding to 
double-stranded DNA. Reactions were performed according with the following 
thermal profile: an initial denaturation (95 °C ,15 minutes) followed by 40 cycles of 
15 sec at 95 °C (denaturation) and 1 min at 60 °C (annealing)  and 20 seconds at 
72 °C (extension). By recording the amount of fluorescence emission at each 
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cycle, the PCR reaction was monitored during exponential phase, where the first 
significant increase in the amount of PCR product correlates to the initial amount of 
target template. The higher the starting copy number of the nucleic acid target, the 
sooner a significant increase in fluorescence is observed. Melting point or 
dissociation curve analysis for amplicon identification, was performed. 
The threshold line is the level of the detection or the point at which a reaction the 
reaction reaches a fluorescent intensity above background (the mean of 
fluorescence values detected from to third to tenth cycle, when target amplification 
it is no appreciable yet) . The threshold was set  placed above baseline activity and 
in the exponential increase phase of the amplification for the most accurate 
reading. The parameter Ct (Threshold cycle) is defined as the fractional cycle 
number at which the fluorescence passes the fixed threshold. The higher the initial 
amount of genomic DNA, the sooner accumulated product is detected in the PCR 
process, and the lower the Ct value. A Ct value of 40 or higher means no 
amplification and this value was not  included in the calculations.  
Results were expressed as ∆∆Ct and presented as ratios between the target gene 
and the GAPDH housekeeping mRNA. All the samples were analyzed in triplicate. 
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9. MTT ASSAY 
Toxicity of dendron 12 was determined by a MTT based assay (In vitro toxicology 
assay kit MTT based, Sigma). The MTT system is a method to measure the activity 
of living cells or tissues  via mitochondrial dehydrogenases activity.  
Viable explants reduce the yellow tetrazolium salt 1-(4,5-dimethylthiazol-2-yl)-
3,5diphenyl formazan  (MTT) to purple formazan  insoluble crystals. 
Explants were cultured in medium culture alone (RPMI medium supplemented with 
20% FBS, penicillin and streptomycin, L-glutamine and gentamycin) or with 
increasing concentration (0.25mM, 0.5 mM, 1 mM) of the compound  12,  diluted in 
medium culture, for 3 and 7 days. Regarding explants treated 7 days, the 50% of 
medium culture  was changed at day 3 with fresh medium containing dendron 12 at 
the concentrations above indicated.   
Media and salt solutions with phenol red contribute to higher background 
absorbance and can decrease sensitivity. Furthermore medium containing more 
than 10% of FBS may form a precipitate when MTT Solubilization Solution is 
added. 
Therefore, after culturing, explants were washed five times in RPMI without phenol 
red (Euroclone). Explants were then incubated in medium RPMI without phenol red 
plus 10% FBS containing MTT (500 µg/ml) for a period of 4 hours.   
Insoluble formazan product was dissolved by incubation with an amount of an 
acidified  Solubilisation Solution (Sigma) equal to original culture media volume.  
The MTT Solubilisation Solution consisted of 10% Triton X-100 plus 0.1 N HCl in 
anhydrous isopropanol. 
Finally formazan absorbance was measured at 595 nm (IMark microplate reader).  
Tissue viability was established by dividing the absorbance reading of the 
formazan by the dry weight of explants. Toxicity was determined  by dividing 
viability of the dendron 12  treated explants by viability of untreated explant control. 
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10. SURFACE PLASMON RESONANCE (SPR) 
Since the development of the first biosensor based on surface plasmon resonance 
(SPR), the use of this technique has progressively increased. Although there are 
several SPR-based systems, certainly the most widely used one is the BIAcore, 
(produced by BIAcore AB) which has developed into a range of instruments.  
The BIAcore presents considerable advantages for analysis of weak 
macromolecular interactions, permitting measurements that are not possible using 
other techniques. The small sample volumes required for BIAcore injections (<20 
µL) make it feasible to inject the very high concentrations (>500 µM) of protein 
required to saturate low affinity interactions. 
SPR-based instruments use an optical method to measure the refractive index 
near (within ~300 nm) a sensor surface. In the BIAcore this surface forms the floor 
of a small flow cell, 20-60 nL in volume, through which an aqueous solution (the 
running buffer) passes under continuous flow (1-100 µL.min-1). In order to detect 
an interaction one molecule (the ligand) is immobilised onto the sensor surface. Its 
binding partner (the analyte) is injected in aqueous solution (sample buffer) through 
the flow cell, also under continuous flow. As the analyte binds to the ligand the 
accumulation of protein on the surface results in an increase in the refractive index. 
This change in refractive index is measured in real time, and the result plotted as 
response or resonance units (RUs) versus time (a sensorgram).  
The BIAcore presents considerable advantages for analysis of weak 
macromolecular interactions, permitting measurements that are not possible using 
other techniques.  
SPR technique has different application. One of these, exploited in this study, is is 
the measurement of equilibrium affinity. 
The small sample volumes required for BIAcore injections (<20 µL) make it feasible 
to inject the very high concentrations of protein required to saturate low affinity 
interactions. Furthermore equilibrium affinity measurements on the BIAcore are 
highly reproducible [126]. 
10.1 Monovalent ligands affinity to DC-SIGN 
The experiments were performed in a collaboration with the Institut de Biologie 
Structurale (Université Joseph Fourier, Grenoble, France). 
DC-SIGN ECD protein (residue 66-404) has been overexpressed and purified as 
described previously [127] All experiments were performed on a BIAcore 3000 
using functionalized CM4 chips and the corresponding reagents from BIAcore. Two 
flow cells were activated as previously described [75].  Flow cell one was then 
blocked with 50 µL of 1 M ethanolamine and served as control surface. The second 
one was treated with BSA-Manα1-3[Manα1-6]Man (BSA-Mannotriose, Dextra) (60 
µg/mL) in 10 mM acetate buffer, pH 4. Remaining activated groups were blocked 
with 50 µL of 1 M ethanolamine. The final density immobilized on the surface of the 
second flow cell was 1200 RU. The BSA-Mannotriose used to functionalize CM4 
chip harbours 15 glycosylation sites according to manufacturer. The affinity of the 
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various compounds was then estimated through a DC-SIGN ECD binding inhibition 
assay. The ECD of DC-SIGN was injected onto the BSA-Mannotriose surface, at a 
concentration of 20 µM, alone or in presence of an increasing concentration of the 
sugar derivatives. Injection were performed at 20 µL/min using 25 mM Tris-HCl, pH 
8, 150 mM NaCl, 4mM CaCl2, and  0,005 % of P20 surfactant as running buffer.  
To determine IC50 values for sugar derivatives, the steady state binding responses 
of DC-SIGN ECD to BSA-Mannotriose surface were obtained from sensorgrams 
and converted to relative residual activity values. Relative IC50 values were 
determined from the plots of sugar derivative concentration vs relative residual DC-
SIGN ECD activity as previoulsly described [128].  
10.2 Selectivity to DC-SIGN and Langerin 
Extracellular domain (ECD) of Langerin (residue 68-328) were overexpressed, as 
inclusion BL21(DE3), refolded and purified to homogeneity in a functional form as 
described [129] DC-SIGN ECD protein (residue 66-404) were overexpressed and 
purified as described. All experiments were performed on a BIAcore 3000 using 
functionalized CM4 chips and the corresponding reagents from BIAcore. Two flow 
cells were activated. Flow cell one was blocked with ethanolamine and used as a 
control surface. The second one was treated with BSA-Manα1-3[Manα1-6]Man 
(Man-BSA, Dextra) (60 µg/mL) in 10 mM acetate buffer, pH 4. Remaining activated 
groups were blocked with ethanolamine.  
The final density immobilized on the surface of the second flow cell was 5200 RU. 
The Man-BSA used to functionalize CM4 chip harbours 12 glycosylation sites 
according to manufacturer. 
The affinities for DC-SIGN ECD and Langerin ECD of pseudo-mannotrioside and 
D-mannose were estimated by an inhibition assay, as described [128,130]. Each 
lectin was injected onto the Man-BSA surface, at 20 µM alone or in presence of an 
increasing concentration of compounds. Injections were performed at 5 µL/min 
using 25 mM Tris-HCl, pH 8, 150 mM NaCl, 4 mM CaCl2, and 0.005% of P20 
surfactant as running buffer. The surface was regenerated by 1’ injection of 50 mM 
EDTA, pH 8. The IC50 values were determined as previously described [128,130]. 
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1. COMPOUNDS 
The following glycomimetics compounds were assayed to evaluate affinity towards 
DC-SIGN and ability to block HIV-1 infection (Fig. 1): 
• Compound 1: a pseudo-disaccharide that shares the three-dimensional 
structure and conformational behavior of Mana1-2Man terminal of Man9. 
The molecule was built by connecting a mannose unit to a conformationally 
locked diol 
• Compound 2b: a pseudo-trisaccharide mimicking the linear mannotrioside 
Manα1-2Manα1-6Manα of Man9  by replacing central mannose unit with a 
carbocyclic diole 
• Compound (or dendron) 11: a tetravalent dendron containing four copies of 
the monovalent compound 1 
• Compound (or dendron)12: a tetravalent dendron containing four copies of 
the monovalent compound 2b 
• Compound (or dendron) 14: a tetravalent dendron containing four copies of 
mannose 
 
Compound 12Compound 2b
Compound 11Compound 1
Compound 14
 
 
Figure1. Chemical structure of the synthesized compounds 
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2. EVALUATION OF MONOVALENT GLYCOMIMETICS AFFINITY 
TO DC-SIGN 
Surface plasmon resonance (SPR) was used to compare the DC-SIGN recognition 
properties of the two monovalent ligands 1 and 2b showed in Fig. 1. As previously 
described, because of the natural low affinity of monovalent compounds to DC-
SIGN, evaluation of their relative affinity cannot be obtained in a direct interaction 
mode, but can only be accessed through a competition assay recently reported 
[131].  
The experiments were performed in a collaboration with the Institut de Biologie 
Structurale of the Université Joseph Fourier (Grenoble, France). For this assay, a 
CM4 SPR chip functionalized with Man-BSA containing 15 glycosylation sites 
displaying the Manα1-3[Manα1-6]Man trisaccharide was used. The DC-SIGN 
extra-cellular domain (ECD) exhibited good affinity (in the µM range) for this 
surface. Inhibition studies were then performed using DC-SIGN ECD, at a fixed 
concentration, injected alone or in the presence of an increasing amount of the 
different ligands. As a reference, a competition experiment has been performed 
with D-mannose.  
The efficiency of inhibition as a function of compounds concentration is directly 
related to the ligand affinity towards DC-SIGN ECD (Fig. 2). An IC50 of 2.51 mM 
was estimated for mannose.  Indeed, within experimental deviations, the IC50 of D-
mannose was in the range of previously reported experiments [132], thus validating 
this test. 
As displayed in the Figure 2, the IC50 of the compounds 1 and 2b was determined 
to be 1.01 mM and 125 µM, respectively. Hence the monovalent ligands 1 and 2b  
displayed an affinity to DC-SIGN much more higher than D-mannose, thus 
confirming a direct contribution of the additional carbocyclic-diol in the binding to 
DC-SIGN CRD. While the interaction properties of the pseudo-disaccharide 1 with 
DC-SIGN have already been demonstrated by NMR [118], it was shown here for 
the first time that its affinity is superior than that of mannose. 
In compound 2b, the addition of a second mannose unit mimicking an α1-6 link and 
resulting in a linear trimannoside mimic, improves the affinity by one order of 
magnitude relative to mannose.  
Both glycomimetic compounds discussed here represented therefore interesting 
ligands to pursue with multivalent versions. Thus, considering affinity to DC-SIGN 
of  the pseudo-disaccharide 1 and of the trimannoside mimic 2b, these compounds 
and the corresponding tetravalent versions were selected to test its capability to 
inhibit the HIV-1 infection in trans infection assay. 
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Figure 2. Comparison of inhibitory properties of different compounds on interaction 
between DC-SIGN and BSA-mannotriose. DC-SIGN ECD at 20 M was incubated 
with mannose (▲), 1 (●), or 2b (■) and injected on a BSA-mannotriose 
functionalized surface. IC50 values are 2.51 mM for mannose, 1.01mM for 
compound 1, and 125 µM for compound 2b. 
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3. EVALUATION OF GLYCOMIMETICS COMPOUNDS ABILITY 
TO INHIBIT HIV-1 TRANS INFECTION DC-SIGN MEDIATED 
3.1 Description of In vitro trans Infection assay  
Synthesized compounds were tested for the ability to inhibit HIV-1 transmission in 
an in vitro trans infection assay. B-THP-1/DC-SIGN cells are derived from B-THP-1 
human B cell line by transfection of DC-SIGN expression vector in order to express 
high levels of the DC-SIGN receptor. This cell line supports efficient DC-SIGN 
mediated HIV transmission and is a widely-used model system to mimic HIV 
capture and transmission to T-lymphocytes by dendritic cells [133]. In a first series 
of experiments, B-THP-1/DC-SIGN cells pre-incubated for 30 minutes in the 
presence or in the absence of the DC-SIGN inhibitors were subsequently exposed 
to (the Clade B R5 tropic laboratory-adapted strain HIV-1 BaL) in the continued 
presence of inhibitors. Mannan is known to inhibit DC-SIGN mediated viral infection 
and was used as positive control (0.25 mg/mL). Non transfected B-THP-1 cells 
were used as a negative control and, as expected, did not transmit infection (Figure 
3). After washing, to eliminate unbound virus and compounds, the B-THP-1/DC-
SIGN cells were co-cultured with activated CD4 T lymphocytes from healthy 
volunteer donors. Viral infection of CD4 T lymphocytes was assessed by 
measuring the concentration of the HIV core protein p24 in the co-culture 
supernatants by ELISA. p24, immunologically distinct from the protein of most 
other retrovirus, is a major structural core component of HIV-1and is estimated to 
be present at 2000-4000 molecules in each virion. Furthermore p24, unlike 
envelope glycoproteins, is well conserved [13]. The measurement of p24 levels is 
therefore a commonly exploited method to verify the successful infection by the 
virus. Each point was obtained in triplicate using CD4 T lymphocytes from at least 
three different healthy donors.  
3.2 Comparison of the monovalent compound 2b and the 
dendron 12 
Initially the monovalent pseudo-disaccharide 1, the monovalent pseudo- 
trisaccharide 2b and mannose were assayed. At 1mM the compound 2b inhibited 
HIV-1 BaL (a R5 tropic laboratory-adapted strain) transmission to CD4 T by over 
the 90%. On the contrary, the compound 1 inhibited only partially the infection and  
mannose failed to inhibit infection even at concentration of 1M (not shown).  
Such results are in accord with the SPR studies described above. Indeed the 
compound 2b displayed the  lowest IC50 and so the higher affinity to DC-SIGN ECD 
among the compounds tested in SPR assay. 
Due to these results, the monovalent 2b was further tested and compared to 
corresponding tetravalent dendron 12. The results obtained showed that the 
tetravalent compound 12 at 50 µM reduced the trans infection of CD4 T 
lymphocytes by over 90%; moreover, at 100 µM and at 250 µM inhibition was 
almost complete. Although the uncertainties deriving from the involvement of three 
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different donors are high in these experiments, the data suggest that higher 
concentrations of the monovalent compound 2b (1 mM and 0.5 mM) are necessary 
to obtain a comparable inhibitory effect. Each point was obtained in triplicate using 
CD4 T lymphocytes from at least three different healthy donors (Fig. 3).  
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Figure 3. Inhibition of HIV transmission after treatment with 2b and 12. After 30’ of 
preincubation with 2b and 12, B-THP-1/ DC-SIGN cells or B-THP-1 cells were 
incubated for 3 h with HIV-1 BaL in the presence of the indicated concentrations of 
compounds. Mannan (0.25 mg/ml) was used as positive control. Infection was 
assessed by measuring the concentration of p24 in the co-culture supernatants. 
Data were obtained in triplicate, from 3 different healthy donors. Values are mean ± 
SD (Standard deviation). 
 
In a second set of experiments the B-THP-1/DC-SIGN cells were first incubated 
with the inhibitors and then washed with PBS prior to exposure to HIV-1 BaL. In 
this case (Fig. 4) the tetravalent system 12 displayed highly efficient anti-infective 
properties with >94 % of inhibition at 100 µM. On the contrary, the monovalent 
compound 2b, even when used at 5 mM concentration (data not shown), did not 
show anti-infective activity. Although alternative explanations cannot be discarded, 
these data suggest that the tetravalent system possesses significant affinity to DC-
SIGN, which allows it to deploy its antiviral activity and to prevent the interaction 
between HIV gp120 and DC-SIGN even after a washing cycle. On the contrary, the 
affinity of 2b is not sufficient for the DC-SIGN / 2b complex to survive the washing 
step, hence viral transmission can occur when the cells are challenged with BaL. A 
quantitative assessment of the relative potency of 12 and 2b was obtained in dose 
response experiments which will be described below (paragraph 3.3).  
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Figure 4. Effect of cell washing after treatment with the inhibitors. B-THP- 1/DC-
SIGN cells were washed after 30 minutes of incubation with the inhibitor, before 
exposure to HIV-1 BaL. Results obtained with or without intermediate wash step 
are compared. Different concentrations of 2b and 12 were assayed. Mannan (0.25 
mg/ml) was included as a control. Values are mean ± SD. 
 
The distance spanned by two ligand units of 12 at full extension of the dendron arm 
is 28–30 Å at best, too short to allow simultaneous binding to two CRDs of the 
same DC-SIGN tetramer (from the recently published tetrameric model of DC-
SIGN, derived from small-angle X-ray scattering studies, the distance between two 
adjacent Ca2+ sites is close to 40 Å) [127]. Although, depending on protein density 
on the cell surface, simultaneous binding to two CRDs on different tetramers could 
occur. Most probably, the ligand presentation on dendrons  allows achievement of 
a high local concentration of recognition elements. With the use of dendrons, that 
are highly soluble in aqueous medium, this effect is obtained without increasing the 
viscosity of the system. Thus the dendrons are fully compatible with use in 
physiological fluids. 
3.3 Dose reponse curves of monovalent 2b and tetravalent 12  
Owing the previous results the properties of 12 were further analyzed. The protocol 
in which inhibitors were not removed by washing was applied in the following trans 
infection experiments, unless otherwise specified. Dose response curves were 
obtained for the compound 12 using CD4 T lymphocytes from healthy donors B-
THP-1/DC-SIGN cells were challenged with HIV-1 BaL in the presence of 
increasing concentrations of 12. After washing and co-culture with the CD4 T 
lymphocytes viral infection was assessed using analysis of p24 concentration in the 
supernatants. At 100 µM the inhibition of infection was complete for all donors and 
an IC50 of 5 µM could be estimated (Fig. 5).  
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Dose response data were also obtained for 2b and allowed to estimate an IC50 of 
ca. 100 µM for the monovalent ligand (Fig. 5).  
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Figure 5. Dose-response results for dendron 12  and the monovalent compound 
2b. After a pre-tratment with different concentrations of 12 or 2b, B-THP1/DC-SIGN 
cells were exposed for 3 h to HIV-1 BaL in the continued presence of the 
compounds. Experiments were performed on CD4 T cells of 3 healthy donors. 
Each donor was tested in duplicate. Values are mean ± SD. 
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3.4 Comparison  of tetravalent dendrons  
The tetravalent dendron 12 was compared with dendron 11, the tetravalent system 
presenting four 1b units, and with dendron 14, that contains four mannose units 
(see Fig. 1). Results showed that dendron 12 displayed a stronger inhibitory activity 
at both concentrations tested (100 and 10 µM). Notably, at 100 µM the compound 
12 abrogated almost totally HIV-1 BaL transmission to CD4 T lymphocytes. The 
dendron 11 reduced the infection by about about the 85% of the infection, whereas 
the inhibition provided by dendron 14 was only partial (approximately 65%) (Fig.6). 
The results obtained are consistent with the affinity difference estimated by SPR 
studies for the corresponding monovalent binding elements (the linear 
trimannoside mimic 2b contained in 12, the pseudodi-saccharide contained in 
dendron 11,  and mannose contained in dendron 14). 
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Figure 6. Comparison between dendrons 11, 12 and 14. Compounds ability to 
inhibit HIV-1 Bal trans infection was evaluated. Experiments were performed on 
CD4 T cells of  3 healthy donors. Each donor was tested in duplicate.  
Values are mean ± SD. 
3.5 The dendron 12 inhibits the HIV-1 infection induced by X4 
tropic and dual tropic strain 
DC-SIGN can mediate trans infection by both R5 tropic and X4 tropic HIV-1 strains.   
Thus, we next verified the capability of dendron 12 to block transmission of the 
HIV-1 laboratory strain IIIB (X4 tropic) and 89.6 (dual tropic, R5/X4). 
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Results showed that transmission of virus to CD4 T lymphocytes was almost 
completely prevented at 250 and 100 µM and about 90% at 50 µM, when B-THP-
1/DC-SIGN cells were challenged with either viral strains (Fig. 7).  
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Figure 7. Inhibition of trans infection mediated by laboratory-adapted HIV-1 strain 
(IIIB and 86.9). Virus transmission was determined by measuring the concentration 
of p24 in the supernatants. Experiments were performed on 3 healthy donors CD4 
T cells. Values are mean ±SD. 
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3.6 The dendron 12 inhibits the HIV-1 infection induced by 
primary HIV-1 isolates 
In subsequent analyses the primary HIV-1 isolates V6 (R5 tropic) and V17 (X4 
tropic) were utilized; also in this case results indicated an inhibition of HIV-1 
infection with both types of virus > 99% at all concentration tested (Fig. 8).  
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Figure 8. Inhibition of trans infection mediated by primary viral isolates (V6 and 
V17). Experiments were performed on 3 healthy donors CD4 T cells. Values are 
mean ±SD. 
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The anti-infective action is therefore independent of viral tropism as shown by 
inhibition of laboratory-adapted strains and primary isolates with different tropism. 
3.7  Evaluation of dendron 12 antiviral effect duration 
To evaluate the duration of the inhibitory properties of tetravalent dendron 12, B-
THP-1/DC-SIGN cells were treated for either 30 minutes or 2 hours with the 
compound at 250 µM. Dendron 12 was subsequently removed and cells were 
exposed to HIV-1 BaL either immediately thereafter, or after 6 and 12 hours. 
Subsequently B-THP-1/DC-SIGN cells were washed and co-cultured with CD4 T 
lymphocytes as described above. Virus transmission to CD4 T lymphocytes was 
almost completely abrogated at 0 and 6 hours post compound removal; notably, 
infection was still reduced by over 80% after 12 hours. Two hour pre-treatment did 
not appear to prolong inhibitory effect of the compound 12 compared to 30 minutes 
pre-treatment (Fig. 9).  
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Figure 9. Persistence of inhibitory effect of 12 after compound removal.B-THP-
1/DC-SIGN cells were incubated with 12 (0.25 mM) for 30’ or 2 h. After extensive 
washing, cells were pulsed with HIV-1 BaL following 0, 6, or 12 h. Levels of 
infection (determined by p24 concentration in co-culture supernatants) 3 days post 
infection were shown. Experiment was performed on two donors. Each condition 
was tested in duplicate. Values are mean ± SD. 
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The experiments shown in Fig.4 and the time-course studies described in this 
paragraph demonstrate that the antiviral effect of 12 persists after the cells have 
been washed, even for hours (Fig.9). The mechanism of this inhibition after 
removal could be based on the persistency of the multivalent ligand on the receptor 
binding site (slow off-rate of the tetravalent compound from the protein). However 
others mechanism can contribute to this effect (see chapter 4).  
3.8 Dendron 12 ability to inhibit trans infection in presence of 
increasing concentration of HIV-1  
The experiments carried out previously showed that the tetravalent dendron 12, 
blocked almost completely infection in trans of CD4 T lymphocytes when a HIV-1 
Bal concentration corresponding to 10 TCID50 was used. Thus, we examined 
whether the dendron 12 was still able to inhibit the trans infection in the presence 
of increasing viral load. B-THP1/DC-SIGN were used as model to mimic HIV 
capture and transmission to CD4 T cells as above described. B-THP1/DC-SIGN 
cells were pre-incubated 30 minutes in presence or in absence of compound 12  
(250 µM) and afterwards were exposed 3 hours to different inoculums of HIV-1 
BaL, without removing the dendron. Indicated viral load (Fig.10), ranging from 5 to 
80 TCID50 (Tissue Culture Infective Dose TCID50), were assayed.  
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Figure10. Evaluation of dendron 12 ability to inhibit HIV-1 Bal trans infection in 
presence of increasing amounts of the virus. Data were obtained from 3 different 
healthy donors. Each donor was tested in duplicate. Values are mean ± SD. 
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After Bal exposure B-THP-1/DC-SIGN cells were washed, to remove unbound BaL 
and dendron, and then co-cultured with activated CD4 T cells from 3 different 
healthy donors. Levels of viral infection were quantified by measuring amounts of 
HIV core protein p24 in the supernatants of co-cultures by ELISA.  
Non transfected B-THP1 cell (negative control) did not transmit the infection (not 
shown). As expected, when B-THP-1/DC-SIGN cells were exposed to increasing 
viral load infection level raised of CD4 T lymphocytes. At lower viral concentration 
(5 TCID50 and 10 TCID50) inhibition of BaL transmission to CD4 T cells was almost 
complete (more than 99%  and more  than 97% respectively). Even at higher viral 
load, corresponding to 40 and 80 TCID50 the dendron was able to counteract the 
transmission of the virus to CD4 T lymphocytes. Indeed, more than 92% inhibition 
was observed (Fig.10).  
 
This potent inhibitory activity is due both to elevate affinity for DC-SIGN of dendron 
12 pseudo-trisaccaride units and to high avidity of binding, guaranteed by the 
tetravalent presentation on the dendron scaffold.  
Others DC-SIGN inhibitors endowed with high affinity to DC-SIGN have been 
described so far. Dendrons which display complex oligomannoses in high density 
was reported to inhibit binding of gp120 to DC-SIGN with IC50 in the nanomolar 
range [119]. Nevertheless the complexity of the oligosaccharides used limits the 
possibility of a therapeutic application. Gold nanoparticles displaying various linear 
and branched mannosyl oligosaccharides (Manno-GNPs) are potent inhibitors of 
DC-SIGN mediated HIV-1 trans infection of human activated PBMCs [120]. 
However, GNPs may have toxic effects  in consequence of  gold accumulation. 
 
A recent study demonstrate that a vaginal gel formulation of the NRTI tenofovir 
reduced HIV infection by 50% (see paragraph 2.5 of introduction). Tenofovir and 
other topical microbicides can prevent localized infection of target cells in genital 
mucosae. However DCs DC-SIGN+ internalize and transport HIV to secondary 
lymphoid organs, rendering the virus inaccessible to inhibitory effect of the 
microbicides. Therefore inhibition of DC-SIGN is essential to block HIV-1 uptake 
and dissemination from migratory DCs. 
3.9 Evaluation of compounds toxicity towards B-THP-1/DC-SIGN 
cells 
The B-THP-1/DC-SIGN were incubated with dendron 12 30 minutes or 3 hours and 
30 minutes: the same incubation time utilized in trans infection assays.  
7-aminoactinomicyn D (7-AAD) labeling of the cells after the incubation period with 
the dendron 12  showed that the anti-infective properties of the inhibitors are not an 
epiphenomenon due to cell death. The data obtained for 12 indicate that the 
percentage of 7-AAD positive cells (non viable cells) was below 1% and did not 
change significantly in the absence of the compound or in its presence up to 250 
µM (Fig.11).  
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Figure 11.Toxicity of compounds. Percentage of 7-AAD positive B-THP1/DC-SIGN 
cells after 3 h and 30' of incubation with different concentrations of dendron 12, or 
in the absence of inhibitor (Medium). Percentage of 7-AAD was determined by flow 
cytometry. Mean of two different experiments is reported. Values are mean ± SD. 
Results and Discussion 
 
 
65 
 
4. EFFECT OF COMPOUNDS 2b AND 12 ON DC-SIGN 
EXPRESSION 
Compounds 2b and 12 could exert their effect secondarily to the suppression of 
DC-SIGN expression. To examine this possibility, DC-SIGN expression was 
studied by flow cytometry experiments; B-THP1/DC-SIGN cells were stained with 
anti DC-SIGN antibody and both percentage of DC-SIGN positive cells and Mean 
Fluorescence Intensity (MFI) were evaluated after 3 hours and 30 minutes of 
incubation with different concentrations of monovalent compound 2b and 
tetravalent dendron 12, or in the absence of inhibitor. Results showed that 
incubation of cells with the compounds did not modify percentages of DC-SIGN 
positive cells (data not shown). A reduction of MFI was observed after treatment of 
the cells with 12. The effect was dose-dependent: ca 20% reduction of Mean 
Fluorescence Intensity was observed for a 50 µM concentration of 12, up to a 52% 
reduction for a 250 µM concentration of 12. The monovalent ligand 2b was tested 
at higher concentrations (Figure 11).  
The effects observed may be at least partially due to increased internalization of 
DC-SIGN receptors after binding of the dendron. However, the concentration 
required to exert a noticeable effect in the flow cytometry studies seems somewhat 
higher than the infection inhibition concentration. 
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Figure 12. Mean Fluorescence Intensity. B-THP1/DC-SIGN cells were stained with 
anti DC-SIGN antibody or 3 hours and 30 minutes of incubation with different 
concentrations of 2b and 12, or in the absence of inhibitors (Medium). Mannan at 
0.25 mg/mL is included as a reference. MFI was determined by flow cytometry. 
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The dose-dependent reduction in MFI observed in the flow cytometry studies 
suggests that exposure to 12 may also alter somewhat significantly the observed 
cell surface concentration of DC-SIGN, possibly by induced endocytosis.  
Depletion of receptor membrane concentration is an interesting feature of dendron 
12 and could at least partially account for its antiviral activity. Complex 
mechanisms can be involved, and for this reason further studies are in progress to 
quantitatively understand the correlation between ant-infectivity and modification of 
cell-surface receptor concentration in this system, as well as to establish the 
underlying mechanisms. 
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5. SELECTIVITY OF  DENDRON 12 TOWARDS DC-SIGN AND 
LANGERIN 
Unlike DC-SIGN, the C-Type lectin receptor Langerin, expressed on Langerhans 
cells (LCs) appears to play a protective role against HIV infection. LCs are located 
in the stratified mucosal epithelia of female and male genital tissue. Both DC-SIGN 
and Langerin recognise high mannose glycan on gp120 through their CRD. Recent 
data demonstrate that Langerin prevent HIV transmission by LCs, at least in the 
presence of low concentration of the virus, promoting rapid degradation and 
clearance of HIV-1 [124,125]. 
Therefore, compounds designed to inhibit DC-SIGN could be of valuable interest if 
they were specific enough to avoid Langerin inhibition.  
Both Langerin and DC-SIGN are able to recognized high mannose present on 
gp120, but have distinct specificities towards complex oligosaccharides.  
Thus, specificity of pseudo-mannotrioside ligand for Langerin and DC-SIGN has 
been tested. Competition experiments using surface plasmon resonance (SPR) 
have been performed as previously described [131]. A CM4 sensorchip has been 
functionalized with BSA-Mannotriose and a fixed amount of the extracellular 
domain (ECD) of both lectins, DC-SIGN and Langerin, were injected over the 
surface in the presence or absence of pseudo-mannotrioside or mannose as a 
control. From the inhibition curves (Fig. 13a), an IC50 of the two ligands towards 
each lectins can be evaluated and compared (Fig. 13b). A limited, if any, difference 
in favour of DC-SIGN is observed for mannose with an IC50 of 3.4 mM towards DC-
SIGN vs 10.3 mM towards Langerin (only a factor of 3). On the contrary, for the 
pseudo-mannotriose, IC50 of 0.25 mM and 5 mM has been measured towards DC-
SIGN and Langerin respectively. 
So, while natural D-mannose does not discriminate between both lectin, the 
pseudo-mannotrioside, contained in dendron 12, is 20 times more potent toward 
DC-SIGN than against Langerin. Moreover, from D-mannose to pseudo-
mannotrioside the inhibitory potency towards DC-SIGN is increased by a factor 14. 
Indeed, the use of allows real improvement in affinity but more importantly in 
selectivity for its use onto multivalent presenting scaffold to target more specifically 
DC-SIGN+ cells within a complex human cervical tissue. Thus, the fact that the 
dendron 12 does not interfere with the function of Langerin is a remarkable 
advantage in view of developing new microbicide compounds. 
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Figure 13. SPR experiment results of DC-SIGN ECD and Langerin ECD binding to 
Man-BSA/dextran surface inhibition by pseudo-mannotrioside (psTri) and D-
mannose. (a) inhibition curves, the compound concentration is expressed in µM. 
(b) lectin selectivity histograms. 
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6. INHIBITION OF HIV-1 INFECTION OF HUMAN CERVICAL 
TISSUE BY DENDRON 12 
Experimental models based on infection with HIV of explants taken from human 
uterine cervix, albeit with some limitation, allows a better approximation of the 
conditions in vivo compared to cellular models. Therefore these models are used to 
evaluate the effectiveness in inhibiting infection by the virus and the potential 
toxicity of candidate compounds to develop as vaginal microbicides [36,37,39]. 
Thus, owing to the results obtained in trans infection assay, a cervical explant 
model was exploited to assess the efficacy of the tetravalent dendron 12 in 
inhibiting HIV infection and its potential toxicity, with the purpose of evaluating if the 
compound is a suitable candidate for the development as topical microbicide.   
Endocervical tissue was obtained from premenopausal women, HIV, HBV and 
HCV seronegative, undergoing planned therapeutic hysterectomy.  
Endocervix is more susceptible to HIV-1 being lined by a single layer of columnar 
epithelium and contains DC-SIGN+ DCs in the subepithelial region [19,35,45]. 
Explants were extensively washed to eliminate traces of Betadine, a broad 
spectrum topical microbicide applied before hysterectomy, that could interfere with 
HIV infection of cervical explants [35]. In a preliminary phase, to develop the 
infection assay, immuno-activated explants (with IL-2 and PHA) or explants not 
activated were infected with a range of concentrations of HIV-1 different strains, in 
order to determine the optimal conditions of infection. The choice of the range of 
concentrations tested was based on data in the literature. 
The explants were placed in contact with the virus in a non-polarized manner, thus 
mimicking the situation where the integrity of genital epithelium is compromised in 
vivo (a condition that significantly increases the risk of becoming infected with HIV). 
The results, obtained by determining the p24 protein in the supernatant of cultures 
of the explants, allowed to individuate the optimal concentration of virus to use. The 
highest infection levels were reached in the third and seventh day post infection 
and then tended to decline, probably due to the deterioration of the explants 
following a prolonged culture. As regarding R5 tropic strains (BaL, DU 174 and 8g) 
were found that levels of infection are similar in explants stimulated and not 
stimulated (not shown) According with the literature data [36]. On the contrary the 
X4 tropic strain required pre-activation. 
6.1 Inhibition of HIV-1 BaL infection  
As the laboratory adapted R5 strain HIV-1BaL is able to infect resting tissue, 
explants were not activated  with IL-2 and PHA to mimic physiological conditions. 
Explants were pre-treated 30 minutes in absence or in presence of different 
concentration of dendron 12 and then were exposed to HIV-1 BaL (2.6 x104 
TCID50) in the continued presence of 12. After washing to remove unbound 
dendron and virus, explants were maintained in culture up to 7 days. Supernatants 
of tissue culture were collected at day 3 and 7 post infection and p24 
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concentration, as measure of HIV-1 BaL infection, was determined by ELISA 
(Fig.14).  
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Figure 14. Inhibition of endocervical tissue infection mediated by HIV-1 Bal. 
Infection was monitored by ELISA measurement of p24 in explant culture 
supernatants at day 3 (a) and 7 (b) post infection. Values represent the mean ±SD 
of 5 independent experiments. ***p values < 0.001, **p values<0.01, *p 
values<0.05 (Student’s T Test). 
 
To obtain dose-response curves 5 different concentration of dendron 12 were 
assayed (1mM, 0.5 mM, 0.25 mM, 0.1mM and 0.01 mM). Data represent p24 
levels 3 and 7 days after infection and are presented as the mean of 5 independent 
experiments, using explants from separate donors. The dendron 12 inhibited 
Results and Discussion 
 
 
71 
 
cervical explants HIV-1 BaL infection in dose dependent manner. At the higher 
concentration  tested (1mM), the compound reduced the infection by about 80%, 
both at 3 and 7 days post infection. An IC50 of 100 µM could be estimated. 
6.2 Inhibition of primary HIV-1 isolates infection 
The ability of dendron 12 to avert explant infection mediated by from primary HIV-1 
isolates was also verified. (Fig.15 and Fig.16).  
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Figure 15. Inhibition of endocervical infection induced by HIV-1 primary isolate 8g 
at 3 (a) and 7 days (b) post infection. Values represent the mean ±SD of 3 
independent experiments performed on cervical explants of 3 separate donors, *p 
values<0.05 (Student’s T Test). 
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R5 tropic isolate 8g was able to infect unstimulated tissue. On the contrary X4 
tropic isolate DPMVF needed pre-activation with IL-2 and PHA to induce consistent 
infection levels (not shown). Explants unstimulated or stimulated 2 days with IL-2 
and PHA were pre-treated with increasing concentration of dendron 12 and 
infected with 8g or DPMVF respectively, as described before. 
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Figure 16. Inhibition of endocervical infection induced by HIV-1 primary isolate 
DPMVF at 3 (a) and 7 days (b) post infection. Values represent the mean ±SD of 3 
independent experiments performed on cervical explants of 3 separate donors, *p 
values<0.05 (Student’s T Test). 
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Infection inhibition was dose dependent both at 3 and at 7 days post infection. 
Regarding 8g, at the concentration of 1mM of dendron 12 infection was reduced by 
about 90% at 3 days and 85% at 7 days after the infection. At 0.05 mM a decrease 
of 45% (day 3 post infection) and of 60% (day 3 post infection) of p24 production 
was still observed (Fig. 15). The compound 12 decreased DPMVF infection by over 
85% at the higher concentration assayed (1mM),  but  at 0.05 mM the inhibitory 
effect was largely lost (Fig 16). 
6.3 Inhibition of HIV-1 DU174 infection 
The HIV-1 Subtype C largely predominates in Southern and East Africa and in 
areas of Asia, where the great majority of infected people reside, and it has caused 
the world's worst HIV epidemics.  
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Figure 17. Dendron 12 activity against  HIV-1 Clade C DU174. Values represent 
the mean ±SD of 3 independent experiments. *p values<0.05 (Student’s T Test). 
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Thus, we evaluated the capability of 12 to block endocervical explant infection 
induced by Clade C R5 tropic strain DU174. Unstimulated explants were pre-
treated with the dendron, exposed to HIV-1 DU 174 (2x104 TCID50) and cultured as 
described above. The results obtained showed that the compound 12, at 1 mM, 
reduced DU 174 infection by about 90% Inhibition  was dose dependent and IC50 
was less than 50 µM both at 3 and 7 days post infection (Fig. 17). 
 
R5-tropic viruses strains predominate during HIV-1 transmission in vivo and cause 
the majority of new infections [8]. The results showed  in this chapter demonstrated 
that the dendron 12 strongly reduced the infection of cervical explants by different 
HIV-1 R5 tropic strains. In effect the compound inhibited infection by the clade B 
laboratory adapted strain BaL and by the primary isolate 8g in dose dependent 
manner. Remarkably the dendron, at the higher concentration assayed, decreased 
the infection induced by the clade C strain DU 174 by about the 90%. This  may 
have a great impact, considering that clade C is the most abundant subtype in 
countries with the majority of HIV-1 infections. Subtype C is present the eastern 
Africa and predominates in all countries of Southern Africa and in some countries 
of Asia [13,14]. Rare cases of HIV-1 infection by X4-tropic strains were observed in 
CCR5∆32 homozygotes [11] and X4 tropic strain can infect immune activate 
human cervical tissue [36]. Our experiments  indicate that the clinical isolate X4 
tropic DPMVF can infect explants stimulated with IL-2 and PHA. Dendron 12 was 
able  to inhibit DPMVF primary X4 tropic strain infection at higher concentration 
assayed, but this effect was in part lost at lower concentrations of the compound. 
 
Vaginal epithelium has limited permeability to particles greater than 30 nm [2]. 
However the diameter of dendron 12 is certainly below that threshold, so the 
compound could enter and diffuse into intact mucosal tissue. Furthermore the 
dendron 12 scaffold can be easily modified to improve absorption of the 
compound, without decreasing affinity to DC-SIGN. 
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7. INDUCTION OF β1 CHEMOKINES PRODUCTION BY 
DENDRON 12 
We wonder if, in addition to competitive inhibition of DC-SIGN, other mechanisms 
account for the antiviral effect of the compound 12. So we investigate if the 
dendron 12 stimulates the production of factors interfering with HIV infection.  
Because of the paucity of submucosal DCs in cervical explants, immature 
monocytes-derived dendritic cells (iMDDCs) from healthy donors were used as a 
model. Experiments were performed on iMDDCs differentiated  by culturing CD14+ 
monocytes, isolated from peripheral blood of donors, for 6 days in presence of IL-4 
and GM-CSF. 
iMDDCs were treated with dendron 12 (250µM) for 3, 24 and 72 hours. Expression 
and production of β chemokines, MIP-1α, MIP-1β, and RANTES, following 
stimulation was analyzed by quantitative real time PCR and ELISA. 
Treatment with 12 increased expression level of mRNA specific for MIP-1α, MIP-1β 
and RANTES about 3, 5 and 4 times respectively (Fig. 18 a-c). 
MIP-1α production increased by about four times and MIP-1β by about 2 times 
after 24 and 72 hours of stimulation (Fig. 19 a, b). RANTES production augmented 
by about 7 and 5 times at 24 and 72 hours respectively (Fig. 19 c).  
These data suggest that  dendron 12 might have additional mechanisms of action 
besides competitive inhibition of HIV-1 binding to DC-SIGN and downregulation of 
DC-SIGN expression. MIP-1α, MIP-1β and RANTES are the natural ligands of 
CCR5, a chemokine receptor and co-receptor of HIV-1 R5 tropic strain. These β 
chemokines suppress HIV-1 R5 tropic strain replication, directly competing with the 
binding of the virus to CCR5 or inducing receptor internalization [9,10,11].  
The compound 12, enhancing β-chemokines production, could interfere, at least 
partially, with the direct infection of CCR5+ CD4 T lymphocytes  and macrophages 
located in genital mucosae. 
As a result of difficulty of isolating sufficient amounts of primary mucosal DCs, 
iMMDCs were used as model. Although MDCCs share with immature mucosal DCs 
similar features and the expression of DC-SIGN and other markers, they do not 
completely mimic function of primary DCs. Therefore we intend to isolate mucosal 
DCs to further investigate the effect of the compound. 
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Figure 18. (a-c) β chemokines expression following 3h dendron 12 (250 µM) 
treatment. mRNA levels of MIP-1α (a), MIP-1β (b) and RANTES (c) were assessed 
by quantitative real time PCR. Expression is normalized to GAPDH expression and 
shown as fold changes expression from the unstimulated sample, set as 1. 
Experiments were performed on iMDDCs from 2 healthy donors. Values represent 
the mean ±SD. 
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Figure 19. (a-c) β chemokines protein production after stimulation with dendron 12 
(250 µM). The concentration of MIP-1α (a), MIP-1β (b) and RANTES (c) in the 
culture supernatants was assayed by ELISA at 24 and 72h. Experiments were 
performed on iMDDCs from 2 healthy donors. Values represent the mean ±SD. 
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8. EVALUATION OF DENDRON 12 TOXICITY 
Cytotoxicity against PBMCs was evaluated by labelling with 7-Amino-Actinomycin 
D (7-AAD), that identifies non-viable cells. The results obtained indicate that the 
dendron 12 exposure for 3 and 7 days did not alter significantly the viability of 
PBMCs at the concentrations assayed (Fig. 20). 
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Figure 20. Toxicity of compound 12. Percentage of 7-AAD positive (non viable) 
PBMCs after 3 or 7 days of incubation with different concentrations of 12 (0.25 mM, 
0.5 mM and 0.1 mM), or in the absence of the inhibitor (Medium). Percentage of 7-
AAD was determined by flow cytometry. Experiments were performed on PBMCs 
from 3 healthy donors. Values are mean ± SD. 
 
To assess potential toxicity of dendron 12 towards cervical tissue, effect of non 
polarized exposure of the compound on cervical explants viability was monitored 
(Fig. 21). After 3 and 7 days treatment in absence or in presence of different 
concentration of compound 12, explants viability was evaluated by a MTT based 
assay. Formazan absorbance reading was normalized to explant weight. Viability 
of the compound treated explants were compared to viability of untreated control. 
The results showed no significant difference between control and treated explants 
up to a maximal concentration of 1mM (the higher concentration tested in 
assessment of dendron 12 efficacy against HIV-1 infection). 
The compound 12 do not reduce the vitality of PBMCs and of cervical explants.  
However additional experiments, such as rabbit vaginal irritation (RVI) assay or 
studies in primate models [134], would be needed for a more accurate evaluation 
of potential toxic effects. 
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Figure 21. Effect of dendron 12 on cervical explants viability. Endocervical 
explants, derived from the same donors, were exposed in non polarised manner to 
12 or culture medium (control) for 3 and 7 days.  Effect of dendron 12 on tissue 
viability was determined by the MTT assay. Explants  were weighted  to normalize 
optical density of formazan yielded. Viability was expressed as percentage, dividing 
viability of compound 12 treated explants by viability of control explant. 
Experiments were performed on explants from 3 donors. Data are reported as the 
average percent viability (± SD). 
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In the absence of an effective protective vaccine against HIV-1, topical 
microbicides represent a possible and promising alternate way to prevent sexually 
transmitted HIV-1 infection. Considering the role of the C-type lectin receptor DC-
SIGN in the first stages of sexually-transmitted HIV infection, the most frequent  
route of HIV-1 transmission, the possibility of inhibiting this receptor in order to 
prevent HIV-1 infection was explored. 
 
The ligand recognized by DC-SIGN on the HIV surface is the high mannose 
glycan, a branched oligosaccharide expressed in multiple copies on HIV gp120. 
A series of monovalent and polyvalent pseudo-mannosylated compounds was 
designed in the attempt to compete with the binding of HIV gp120 to DC-SIGN.  
 
The binding affinity of the synthesized compounds to DC-SIGN was evaluated by 
Surface Plasmon resonance studies (SPR). The ability of such compounds to 
inhibit HIV infection was assessed in a in vitro model of trans infection. Productive 
HIV infection was monitored by measuring HIV core protein p24 in the 
supernatants of cell culture. 
 
One of these compounds, a tetravalent pseudo-mannosylated compound (dendron 
12), competitively inhibited DC-SIGN mediated HIV trans infection of CD4 T cells at 
low micromolar range, regardless of viral strain, even in the presence of elevated 
viral loads. The time-course studies, described in the results section, demonstrated 
that the antiviral effect of dendron 12 persists for hours even after the compound 
have been removed. This long-lasting inhibition after removal could be due to the 
persistency of the dendron 12 binding to DC-SIGN. The reduction of DC-SIGN 
expression following the binding of dendron 12 may also contribute to this effect. 
 
In the attempt to clarify the mechanisms of action of this compound a biosensor 
with a SPR detection method was employed. Results showed that compound 12 is 
much more selective for DC-SIGN than for the C-type lectin Langerin, expressed 
by Langheran’s cells. Considering the similarity between the carbohydrate 
recognition domain of DC-SIGN and Langerin (that prevents HIV transmission 
promoting the rapid degradation and clearance of this virus), the fact that the 
dendron 12 does not interfere with the function of Langerin is a remarkable 
advantage in view of developing new microbicide compounds. 
 
To further assess the ability of the compound to inhibit HIV-1 infection, a model 
based on the infection with different HIV-1 strains of explants taken from human 
uterine cervix was utilized. Explants were obtained from HIV-, HBV-, and HCV-
seronegative premenopausal women, undergoing planned therapeutic 
hysterectomy. After dendron 12 pretreatment, explants were exposed to different 
HIV-1 strains in a non polarised manner, mimicking a condition of compromised 
epithelium in vivo (a condition that highly increase the risk of HIV infection). Viral 
infection was quantified by measuring HIV core protein p24 concentration in 
explant culture supernatans at different time points. As R5-tropic viruses 
predominate during HIV-1 transmission in vivo and cause the majority of new 
infections, the ability of dendron 12 to avert the infection of cervical explants by 
different HIV-1 R5 tropic strains was evaluated. Results showed that the compound 
strongly inhibits infection by the clade B laboratory adapted strain BaL and by a R5 
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primary isolate in a dose dependent manner. Remarkably the dendron decreased 
the infection induced by the clade C strain DU 174 by more than 90%. This may 
have a great impact, considering that clade C is the most abundant subtype in 
Southern Africa and in areas of East Africa and Asia, where the great majority of 
HIV infected people reside. 
Rare cases of HIV-1 infection by X4-tropic strains were observed in CCR5∆32 
homozygotes and X4 tropic strain can infect immune activate human cervical 
tissue. Experiments performed indicate that dendron 12 was able  to inhibit DPMVF 
primary X4 tropic strain infection at higher concentration, but this effect was in part 
lost at lower concentrations of the compound. 
  
The competitive inhibition of HIV-1 binding to DC-SIGN is one of the mechanisms 
by which the compound exerts its effect. To verify whether dendron 12 might have 
additional mechanisms of action besides competitive inhibition of HIV-1 binding to 
DC-SIGN additional experiments were performed. Results showed that dendron 12 
elicits production of the β chemokines MIP-1α, MIP-1β and  RANTES by monocyte 
derived DCs. These chemokines suppress HIV-1 R5 tropic strain  replication, 
directly competing with the binding of the virus to CCR5 or inducing receptor 
internalization. Therefore compound 12 likely interferes with the infection of CCR5+ 
CD4 lymphocytes, DCs and macrophages located in genital mucosae by  
enhancing β-chemokines production. 
 
Thus, this work shows that the tetravalent dendron 12 is able to prevent HIV trans 
infection of CD4 T lymphocytes at low micromolar range, even in presence of 
elevated viral load, is devoid of toxicity and inhibits in a dose dependent manner 
the HIV-1 infection of human cervical explants. Furthermore the compound is 
highly soluble in physiological media and is stable at acidic vaginal pH. These 
features make the dendron 12 an optimal compound in the design of new 
microbicidal drugs. Indeed the development of innovative topical microbicide drugs, 
such as dendron 12, may have a considerable impact on human health.  
 
However the compound 12 is able to inhibit 80-90% of cervical explants HIV-1 
infection, but cannot block it completely. To overcome these limitations, different 
lines of study are in progress in our laboratories.  
Structure of dendron 12 can be improved in both the scaffold and the active 
pseudo-saccharide ligand to develop of new ligands of DC-SIGN even more 
effective in inhibiting infection and easier to synthesize than the original lead. 
Furthermore, dendron 12 (or its derivatives) can be used in combination with other 
molecules directed against different HIV targets. Indeed, the combinations reported 
so far were all found to display synergistic activity in infection assays. In particular 
mixed multivalent structures, presenting on the same scaffold multiple copies of 
DC-SIGN and HIV co-receptors ligands, simultaneously blocking different HIV 
target, could protect against different routes of HIV transmission. Hence such 
structures could represent a highly promising strategy to prevent the first phases 
HIV infection. 
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